[{"text": "Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting PR Newswire Mon, Jan 27, 2025, 4:00 PM 6 min read In This Article: AORT -1.20% Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the \"IDE\") was presented in a Late-Breaking Science presentation at the 61 st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California . The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation. (PRNewsfoto/Artivion, Inc.) Dr. Shinichi Fukuhara , Division of Cardiac Surgery, University of Michigan , presented the data from the PERSEVERE US IDE trial (NCT05174767) as a late-breaking abstract titled, One-Year Results of a Novel Aortic Arch Hybrid Prosthesis for Open Repair of Acute DeBakey Type I Dissection with Malperfusion in the PERSEVERE Study. Data from the trial demonstrate sustained benefit of AMDS out to one year showing minimal new occurrence of stroke, renal failure requiring dialysis, or myocardial infarction. 80% of patients survived through 1-year with mortality after 30-days attributed to comorbidities and dissection-related complications. Primary Endpoints PERSEVERE (N=93) Historical Controls 1 30-Days (%) 1-Year (%) 30-Days (%) 1-Year (%) All-Cause Mortality 9.7 20.4 34.6 42.7 New Disabling Stroke 10.8 11.8 20.9 NR New Renal Failure/Dialysis 19.4 20.4 24.1 NR Myocardial Infarction 0 2.2 10.5 NR Total # with \u2265 1 MAE 26.9 30.1 58.0 NR DANE 0 0 45.0 NR 1 NR = Not Reported Further, core lab analysis of follow up CT scans suggests AMDS prevents the occurrence of distal anastomotic new entry (DANE) tears which compares favorably to expected rates of early reintervention and DANE tears in this patient population. DANE tears occur in up to 70% of patients following hemiarch repair without AMDS, allowing continued blood flow into the false lumen created by the dissection. 1,2 The presence of DANE is associated with enlargement of the aorta, reoperation, and increased mortality.\u00a0In contrast, DANE has not been detected in any patients in the PERSEVERE study and it was not reported in the DARTS study through 5 years of follow up of AMDS-treated patients. 3 The need for unanticipated aortic reoperations was low at 4.3% 4 . Dr. Fukuhara commented, \"Patient outcomes following AMDS treatment of acute DeBakey Type I aortic dissection with malperfusion remain impressive through one year after operation. AMDS is an important tool for cardiovascular surgeons in treating this devasting disease.\" Story Continues \"We are very pleased to see such clinically meaningful one year data for AMDS, particularly the complete avoidance of DANE tears. These data build on the positive findings from the 30-day readout and validate with the groundbreaking, lifesaving nature of AMDS,\" said Pat Mackin , Chairman, President, and Chief Executive Officer of Artivion. \"We look forward to bringing AMDS to more patients through our recently received Humanitarian Device Exemption (HDE) while continuing our work with FDA towards PMA approval, which we still expect to receive in late 2025.\" About the AMDS PERSEVERE Clinical Trial The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS Hybrid Prosthesis. The trial is designed to support the Company's forthcoming application to the U.S. Food and Drug Administration (FDA) for premarket approval of the AMDS. The trial consists of 93 participants in the U.S., who have experienced an acute DeBakey Type I aortic dissection complicated by malperfusion. Each participant will be followed for up to 5 years. 30-day trial data met combined safety and primary efficacy endpoints demonstrating significant reduction of major adverse events (MAEs), including all-cause mortality, stroke, renal failure requiring dialysis, and myocardial infarction following AMDS implantation. The secondary endpoint relates to remodeling of the aorta. About the AMDS Hybrid Prosthesis and Acute DeBakey Type I Aortic Dissections The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. It is used as a complement to, and in conjunction with, hemiarch replacement without adding technical complexity. The design of the AMDS allows for rapid deployment of the graft in the aortic arch during a standard replacement of the ascending aorta, with deployment adding minimal time to the procedure. The deployment of the AMDS preserves the native arch, allowing for minimally invasive re-interventions if needed, rather than an invasive arch repair. AMDS is available in the United States under an HDE and in select markets around the world including Europe , Canada and certain countries in Asia . The PERSEVERE clinical trial underpinning the AMDS PMA met its primary endpoints and demonstrated a 72% reduction in all-cause mortality and a 54% reduction in primary major adverse events (MAEs), with zero occurrence of distal anastomotic new entry, or DANE, when compared to the current standard of care hemiarch procedure at 30-days following AMDS implantation. In the clinical trial (DARTS) supporting the CE Mark and Health Canada approvals, the AMDS was shown to reduce complications and reoperations in comparison to published rates with the standard of care, thereby improving the care of patients and offering potential cost savings for the health care system. Globally, approximately 48,000 patients suffer annually from acute DeBakey Type I aortic dissections, representing an estimated $150 million market opportunity in the United States and $540 million market opportunity globally, pending regulatory approvals. Aortic dissection occurs when the innermost layer of the aorta tears and blood surges through the tear separating the layers of the aorta. In acute DeBakey Type I aortic dissections, the dissection flap originates in the ascending aorta and continues down into the descending thoracic aorta. Left untreated, aortic dissections lead to death in about half of patients within the first 3 days.\u00a0The current standard of care for repairing acute DeBakey Type I aortic dissections with a primary entry tear in the ascending aorta is a hemiarch repair which involves open chest surgery during which the ascending thoracic aorta is replaced. Though this typically addresses the most critical and pressing issues resulting from acute DeBakey Type I dissections, it is often not enough. Hemiarch repair alone does not address downstream true lumen expansion or treat the false lumen beyond the ascending aorta, which could lead to costly and fatal complications such as malperfusion with subsequent end-organ ischemia resulting from a lack of blood-flow and continued pulsatile blood flow in the false lumen leading to aneurysmal growth of the aorta. About Artivion, Inc. Headquartered in suburban Atlanta, Georgia , Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com . References Ravesh M. et al. J Thorac Dis 2021 Bing F et al. Vasc Endovasc Surg 2014, Ergin M, et al Ann Thorac Surg 1994, Rylski B et al. Eur J Cardiothorac Surg, 2017, Tamura K et al, Eur J Cardiothorac Surg 2017 Internal data (pending publication) El-Andari R, Moon M, Bozso S. 5-Year Results on Aortic Remodeling in the Dissected Aorta Repair Through Stent (DARTS) Implantation Trial. 38 th European Association for Cardio-Thoracic Surgery (EACTS) Conference. Lisbon, Portugal . Contacts: Artivion Lance Berry Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Laine Morgan Phone:\u00a0 332-895-3222 investors@artivion.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/artivion-announces-presentation-of-late-breaking-data-from-amds-persevere-trial-at-the-61st-society-of-thoracic-surgery-annual-meeting-302360153.html SOURCE Artivion, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2025-01-27T13:00:00+00:00", "sentiment": {"score": 0.054295629262924194, "confidence": 0.09612333029508591, "probabilities": {"positive": 0.09612333029508591, "negative": 0.04182770103216171, "neutral": 0.8620489835739136}}, "embedding": [-0.06148259714245796, 0.019311923533678055, 0.09968988597393036, -0.014940978027880192, -0.05081472545862198, -0.11215515434741974, -0.17906907200813293, 0.16663846373558044, 0.19453558325767517, 0.08009501546621323, -0.07934325933456421, 0.11686951667070389, 0.002212725579738617, 0.047129079699516296, -0.1922200620174408, -0.013633538037538528, 0.08694320917129517, 0.04195573180913925, -0.06111042574048042, 0.20903977751731873, 0.06670257449150085, 0.01826724037528038, -0.03877252712845802, -0.04313640296459198, 0.0202033668756485, -0.033267952501773834, -0.12472930550575256, -0.014849383383989334, -0.0618431456387043, 0.0016376348212361336, 0.07582471519708633, -0.054798878729343414, 0.03480474650859833, -0.05589062720537186, -0.0323571152985096, 0.08801999688148499, -0.001805485924705863, 0.062388934195041656, -0.24100619554519653, 0.037158817052841187, 0.0031318897381424904, 0.021456874907016754, -0.12117615342140198, -0.047808535397052765, 0.03487804904580116, -0.07411904633045197, -0.1721421778202057, -0.006866873241961002, -0.07420842349529266, 0.22557353973388672, -0.18578581511974335, -0.020820792764425278, -0.1647683084011078, 0.02879413217306137, 0.03663736581802368, -0.04639754444360733, -0.07374154776334763, -0.09095993638038635, -0.08874772489070892, -0.02945427969098091, -0.018496504053473473, 0.07533426582813263, -0.023812485858798027, 0.011593488976359367, -0.1095268577337265, -0.0029590479098260403, 0.09796052426099777, -0.09904029965400696, 0.05700908601284027, -0.1083284392952919, 0.1800626665353775, -0.06594765186309814, 0.008318722248077393, 0.05374966561794281, -0.01908145472407341, 0.14293509721755981, 0.03449937701225281, -0.04374586418271065, -0.03383500874042511, -0.08912473917007446, 0.045073628425598145, 0.11902143061161041, 0.032710060477256775, -0.06245461851358414, 0.06323278695344925, 0.008729672990739346, -0.04237388074398041, 0.09434840828180313, 0.010017277672886848, 0.015517471358180046, 0.03633863106369972, 0.02452109381556511, -0.055746257305145264, -0.024480989202857018, 0.18356378376483917, 0.008503605611622334, -0.09200786054134369, 0.0379464328289032, -0.00697881355881691, -0.10562632977962494, -0.014273661188781261, 0.09933942556381226, -0.10040730983018875, -0.07768511772155762, -0.04755033180117607, -0.07643232494592667, 0.07160990685224533, -0.165755033493042, 0.0629270076751709, -0.095128133893013, 0.05927043408155441, 0.08946014940738678, 0.14499463140964508, -0.023570764809846878, 0.09455911815166473, 0.199194073677063, -0.12634821236133575, 0.12035328894853592, 0.26597341895103455, 0.13520902395248413, 0.023425757884979248, -0.0644734725356102, 0.0866633877158165, -0.07567617297172546, 0.12347951531410217, 0.11524695158004761, 0.01619875431060791, 9.700627540206768e-33, 0.15478861331939697, -0.0420425683259964, -0.017593426629900932, 0.08304071426391602, -0.060549139976501465, -0.06367668509483337, -0.05603371560573578, -0.04206646978855133, 0.05739321559667587, -0.12303196638822556, -0.02497732639312744, -0.02382483333349228, 0.04517202451825142, -0.04542123153805733, -0.048490263521671295, -0.003424183465540409, 0.05591398477554321, 0.04569859057664871, -0.05997055768966675, 0.012328967452049255, 0.070842444896698, -0.04092425853013992, 0.011994089931249619, 0.0003189723938703537, 0.02663390152156353, 0.11480747163295746, -0.0023135831579566, 0.10934318602085114, -0.07588482648134232, 0.013384301215410233, -0.15891645848751068, -0.06720861792564392, 0.04429158195853233, -0.12394046783447266, -0.12327730655670166, -0.032013535499572754, -0.03931722790002823, -0.048698075115680695, 0.017526112496852875, 0.06452392041683197, -0.08817769587039948, 0.0931597650051117, -0.061303213238716125, -0.10335628688335419, 0.07959260046482086, -0.1902482807636261, 0.024303358048200607, 0.06741611659526825, -0.047864481806755066, 0.044961705803871155, -0.038565557450056076, 0.023261116817593575, 0.10756559669971466, -0.12449896335601807, -0.09892559796571732, 0.006591876037418842, -0.06803947687149048, -0.0025194939225912094, 0.060248903930187225, 0.11851035058498383, 0.011862039566040039, 0.1558266580104828, -0.035272493958473206, 0.1812410056591034, -0.06243911013007164, 0.06104348972439766, -0.06592774391174316, -0.08161431550979614, 0.07268369197845459, 0.03293852135539055, -0.1044829785823822, -0.09565870463848114, 0.03632858395576477, -0.06095556914806366, 0.010358748957514763, -0.0014199577271938324, 0.0954323410987854, 0.1295902580022812, 0.029967477545142174, -0.13121449947357178, -0.03602193295955658, 0.15184344351291656, -0.07610903680324554, 0.01346247736364603, 0.08783181756734848, 0.06848558038473129, 0.08763445168733597, -0.07630974799394608, -0.07205794751644135, -0.06480580568313599, 0.143436461687088, -0.04139287397265434, -0.07797566056251526, 0.0409100279211998, -0.04959128797054291, -1.1561983906483489e-32, -0.12252302467823029, 0.042040273547172546, -0.03427831456065178, -0.06069936975836754, 0.02319609373807907, 0.0641394555568695, 0.08132821321487427, 0.030856454744935036, 0.082509845495224, -0.3227739632129669, 0.017597723752260208, 0.0083078071475029, 0.0016117235645651817, 0.042337462306022644, -0.1307763010263443, 0.10278786718845367, -0.0635085254907608, -0.06806407868862152, -0.15291547775268555, 0.07482253015041351, 0.14142084121704102, 0.18283970654010773, 0.0002010650932788849, -0.010558458045125008, 0.012328816577792168, 0.07434206455945969, 0.08011934161186218, 0.006524607539176941, 0.03909426927566528, -0.15499113500118256, 0.1748221516609192, 0.053555943071842194, -0.15204188227653503, 0.024715185165405273, -0.08815102279186249, 0.11092277616262436, 0.06786671280860901, -0.03273584693670273, -0.02434392273426056, -0.0475483313202858, 0.06289749592542648, 0.00958243478089571, -0.0560699999332428, 0.07720592617988586, -0.04204385727643967, -0.0995551198720932, 0.06180281937122345, -0.08429703861474991, 0.22414323687553406, -0.04758423566818237, -0.14652276039123535, -0.052667975425720215, 0.11394387483596802, 0.05011127144098282, -0.00830021034926176, -0.19432300329208374, 0.10808482766151428, -0.05505400896072388, -0.27976322174072266, 0.015639889985322952, 0.009144577197730541, 0.08252118527889252, 0.2083740532398224, -0.0014495470095425844, 0.15444102883338928, 0.10710673034191132, 0.1774684190750122, 0.008639980107545853, -0.08012673258781433, -0.07752986252307892, -0.10511839389801025, -0.044554442167282104, -0.15957675874233246, -0.1724681854248047, 0.10289528965950012, 0.050963032990694046, 0.0037961341440677643, -0.02995382994413376, -0.15422266721725464, 0.06342445313930511, -0.10403410345315933, -0.057680394500494, -0.12891213595867157, -0.016313616186380386, -0.0812658816576004, 0.06967894732952118, 0.05157562345266342, -0.07510650902986526, -0.006527986377477646, 0.06389723718166351, -0.07497545331716537, 0.020915798842906952, -0.08144252002239227, -0.010393492877483368, 0.08779376745223999, -1.0032108122004502e-07, -0.034022893756628036, 0.1467423141002655, 0.01199989765882492, -0.0713764950633049, -0.06657058745622635, -0.21058058738708496, -0.04856523498892784, 0.04647476598620415, -0.14310315251350403, 0.07800234854221344, 0.1745397448539734, 0.17309021949768066, -0.016004839912056923, -0.1397179365158081, 0.014063257724046707, -0.04392402991652489, 0.043131016194820404, 0.019986137747764587, 0.004936219658702612, -0.02807999961078167, -0.014834639616310596, -0.05493259057402611, 0.07366346567869186, -0.18113243579864502, -0.07019494473934174, 0.0038498868234455585, 0.026175782084465027, -0.11695954203605652, 0.00451440317556262, -0.020397214218974113, -0.05653102695941925, -0.05515888333320618, 0.14731043577194214, -0.008291256614029408, -0.02064218558371067, -0.10207417607307434, 0.17969658970832825, 0.13716310262680054, -0.02414805069565773, 0.09868578612804413, 0.09692633152008057, 0.03429272398352623, 0.07671384513378143, 0.09984298795461655, -0.06519071757793427, -0.008630484342575073, -0.16240355372428894, 0.08701160550117493, 0.027076657861471176, -0.017234930768609047, 0.00989578664302826, -0.058432016521692276, -0.02921290695667267, -0.0892219990491867, -0.012357737869024277, 0.10221482813358307, -0.018863799050450325, 0.021591996774077415, -0.007469491567462683, 0.01338292472064495, 0.1807008534669876, -0.10988762974739075, 0.027688708156347275, -0.027401743456721306], "changes": {"1wk": 1.0443854477762455}}, {"text": "Is Artivion, Inc. (AORT) Among Billionaire Joseph Edelman\u2019s Long-Term Stock Picks? Usman Kabir Mon, Jan 20, 2025, 11:23 PM 4 min read We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks . In this article, we are going to take a look at where Artivion, Inc. (NYSE:AORT) stands against other Billionaire Joseph Edelman\u2019s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing. As the founder, CEO, and portfolio manager of Perceptive Advisors , Edelman has built a reputation as one of the most successful and insightful investors in the biotech sector. His deep understanding of the scientific, clinical, and financial aspects of the industry has enabled him to identify promising companies and generate significant returns for his investors. Joseph Edelman earned his Bachelor of Arts in Psychology from the University of California, San Diego, and later pursued an MBA from NYU Stern School of Business. He began his career as a biotechnology analyst at Prudential Securities and subsequently worked as a portfolio manager at Paramount Capital Asset Management. These early roles provided Edelman with a foundation in analyzing biotech companies, understanding their value drivers, and assessing the risks associated with drug development and regulatory approval processes. Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs . In 1999, Edelman founded Perceptive Advisors, a New York-based investment firm focused on the life sciences sector. The firm initially launched with a single hedge fund, the Perceptive Life Sciences Fund, and has since expanded to manage billions of dollars in assets. Perceptive Advisors specializes in identifying high-growth potential in emerging biotech, pharmaceutical, and healthcare companies, with an emphasis on innovation in areas such as gene therapy, oncology, and rare diseases. Under Edelman\u2019s leadership, Perceptive Advisors has achieved remarkable success. The firm manages over $4.7 billion in the 13F portfolio as of the end of the third quarter of 2024. The Perceptive Life Sciences Fund has delivered annualized returns exceeding 15% over the past two decades, far outpacing broader market indices. Edelman has been an early backer of biotech companies that went on to achieve significant breakthroughs, including Moderna and CRISPR Therapeutics. While Edelman\u2019s track record is stellar, the biotech sector\u2019s inherent risks mean that not all investments succeed. Regulatory setbacks, clinical trial failures, and market sentiment can lead to significant volatility. Story Continues Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities . For this article, we selected stocks by combing through the 13F portfolio of Perceptive Advisors at the end of the third quarter of 2024. Only the companies that have been in the 13F portfolio of the fund consistently for the past three years were selected. These stocks are also popular among other hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). Is Artivion, Inc. (AORT) Among Billionaire Joseph Edelman\u2019s Long-Term Stock Picks? A biomedical technician testing and calibrating medical equipment to be deployed. Artivion, Inc. (NYSE: AORT ) Number of Hedge Fund Holders: 17 Perceptive Advisors\u2019 Stake: $6.7 million Artivion, Inc. (NYSE:AORT) is a medical device company specializing in cryogenically preserved human tissues and innovative surgical solutions, notably heart valves and surgical adhesives. There are multiple factors that make Artivion (NYSE:AORT) a golden opportunity to invest in. Firstly, in the third quarter of 2024, the company reported revenue of $95.8 million as compared to $87.9 million in the third quarter of 2023, showing an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis. Secondly, Artivion (NYSE:AORT) has invested an additional $25 million in Endospan to support the Food and Drug Administration approval path for the NEXUS Stent Graft System. It is designed for the aortic arch disease and specializes in controlling 2-stage procedures. Moreover, the company has also received regulatory approval to commercialize BioGlue in China, a significant market with substantial growth potential. Overall, AORT ranks 6th on our list of Billionaire Joseph Edelman\u2019s long-term stock picks. While we acknowledge the potential of AORT as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a stock that is more promising than AORT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2025-01-20T20:23:08+00:00", "sentiment": {"score": 0.27250510081648827, "confidence": 0.2816429138183594, "probabilities": {"positive": 0.2816429138183594, "negative": 0.009137813001871109, "neutral": 0.7092193365097046}}, "embedding": [-0.027706580236554146, -0.08590862900018692, -0.07423064857721329, -0.03199125826358795, -0.04254800081253052, -0.04785354435443878, 0.007826991379261017, 0.05825629085302353, 0.14309394359588623, -0.009741395711898804, -0.05330686271190643, 0.16801786422729492, -0.07558032870292664, 0.012921547517180443, -0.13064002990722656, 0.10985443741083145, -0.021287141367793083, 0.04284480959177017, -0.11393073201179504, 0.08931823819875717, -0.07165727019309998, -0.1252347230911255, -0.010136677883565426, -0.09664357453584671, -0.029177255928516388, 0.0013991082087159157, -0.01893467828631401, -1.730024814605713e-05, -0.21992290019989014, -0.04092646390199661, 0.11986044049263, 0.05237689986824989, 0.08619698137044907, -0.035981759428977966, -0.03831300139427185, 0.16121806204319, -0.03753300756216049, 0.1549621969461441, -0.009164547547698021, -0.01265247818082571, 0.05197001248598099, -0.07092460989952087, -0.09454014152288437, 0.06812641769647598, 0.08637665212154388, -0.1762857437133789, -0.04577086865901947, -0.030653083696961403, 0.04879797250032425, 0.03187805786728859, -0.34671279788017273, -0.16280993819236755, 0.11069818586111069, -0.14656150341033936, -0.10753392428159714, 0.02928530052304268, -0.023673778399825096, 0.09655357897281647, -0.03608456999063492, 0.037512920796871185, 0.05297962948679924, -0.13027644157409668, 0.05292428284883499, 0.015785660594701767, 0.05396765097975731, 0.05667289346456528, 0.036664821207523346, 0.05949697643518448, -0.055991530418395996, -0.09585694968700409, 0.12423525750637054, -0.04986449331045151, -0.06809692084789276, 0.06255177408456802, 0.07896324247121811, 0.04588470607995987, 0.005467449314892292, 0.08586139231920242, 0.1382163166999817, -0.14660745859146118, 0.13391107320785522, 0.016383497044444084, -0.06434399634599686, 0.013988034799695015, -0.059751495718955994, -0.015153167769312859, -0.04774569720029831, 0.019832052290439606, 0.07726956903934479, 0.11256453394889832, -0.035031840205192566, -0.10568876564502716, -0.022359933704137802, -0.032801173627376556, 0.1134197935461998, 0.021342076361179352, -0.12280455976724625, -0.06086457520723343, -0.1393488645553589, -0.02145131677389145, -0.025023875758051872, 0.09452219307422638, -0.1070556640625, 0.09971262514591217, -0.03510402515530586, -0.1011279970407486, 0.045446235686540604, 0.003501088358461857, 0.07618390023708344, 0.05241485312581062, -0.09531012177467346, 0.13798405230045319, -0.05744368955492973, 0.04338407143950462, 0.061427973210811615, 0.005349257495254278, -0.06506424397230148, 0.09720878303050995, 0.22036507725715637, -0.03483789786696434, 0.019641289487481117, 0.09010478109121323, -0.08686333149671555, -0.02480732649564743, -0.0699019581079483, -0.09781871736049652, -0.1888197958469391, 1.2299829220867161e-32, -0.06114096939563751, 0.21692310273647308, 0.06006894260644913, 0.15403036773204803, -0.13810789585113525, -0.008587835356593132, -0.0004506451077759266, -0.01635122485458851, -0.11671951413154602, -0.08047834038734436, 0.013908710330724716, 0.11312700062990189, -0.010013356804847717, 0.1319345384836197, -0.08285272121429443, -0.11370174586772919, 0.010479283519089222, 0.06687728315591812, 0.053833480924367905, -0.07822113484144211, -0.04547286406159401, 0.026460852473974228, -0.13281893730163574, -0.05557997152209282, -0.03943663462996483, -0.04364427924156189, 0.04129171371459961, 0.06014474481344223, -0.0069046905264258385, 0.05429467558860779, -0.022560715675354004, 0.10348407924175262, -0.07609961181879044, -0.09486180543899536, 0.045672863721847534, -0.09692390263080597, -0.06572547554969788, -0.1231713593006134, 0.12148334830999374, 0.07278039306402206, -0.14377394318580627, 0.1355873942375183, 0.02734447456896305, -0.03422563523054123, -0.1006145030260086, 0.03878799453377724, 0.10288700461387634, 0.17468425631523132, 0.11954224109649658, -0.07150812447071075, -0.04115991294384003, 0.012622853741049767, 0.03360883891582489, -0.13261130452156067, 0.007123884279280901, 0.03797841817140579, -0.10347025096416473, -0.03473401069641113, 0.0019859950989484787, 0.015323794446885586, 0.021659549325704575, 0.13272331655025482, -0.08381519466638565, 0.13169792294502258, -0.08529728651046753, 0.11597410589456558, -0.01356329582631588, 0.005262868478894234, 0.027478955686092377, 0.19787991046905518, -0.003588572144508362, 0.0008687041699886322, 0.11719779670238495, -0.10104848444461823, -0.07894819974899292, -0.06703513860702515, -0.044145289808511734, 0.1212489902973175, -0.006837866269052029, 0.11100178956985474, 0.0976855680346489, 0.06359772384166718, 0.03063957393169403, -0.03684758394956589, -0.05246291309595108, 0.06712788343429565, 0.040994808077812195, 0.043504077941179276, 0.06368327140808105, 0.0475676953792572, 0.08649484068155289, -0.08419033885002136, 0.00302687706425786, 0.09212586283683777, -0.06448076665401459, -1.0593672639045537e-32, -0.11416085064411163, -0.1456083059310913, 0.027247298508882523, -0.045705173164606094, 0.05325803533196449, -0.04521937668323517, 0.003070216625928879, -0.001049613580107689, 0.058349575847387314, -0.05413644760847092, 0.031185250729322433, 0.03962656110525131, -0.0020475746132433414, -0.06851080060005188, -0.08368420600891113, 0.05408623814582825, -0.03638940304517746, -0.10322720557451248, -0.06558513641357422, -0.11157022416591644, 0.061773478984832764, 0.11451971530914307, -0.07437636703252792, 0.10183051973581314, -0.04168226197361946, 0.10849788784980774, 0.043367791920900345, 0.14294064044952393, -0.03994216397404671, -0.035684213042259216, -0.02044503390789032, -0.005281809251755476, -0.20070761442184448, 0.011531287804245949, -0.03813910856842995, 0.05341878533363342, -0.09534391760826111, -0.17194947600364685, -0.044555678963661194, -0.02610529586672783, 0.07973610609769821, -0.023320496082305908, -0.00869037862867117, -0.10996778309345245, 0.059169571846723557, 0.04855985939502716, 0.07722196727991104, 0.10138627886772156, 0.13071489334106445, 0.026974521577358246, -0.08046658337116241, 0.12702226638793945, -0.004708055406808853, -0.0110747329890728, -0.042261190712451935, -0.08736000955104828, 0.11695284396409988, 0.0379473976790905, 0.01633293181657791, -0.05139089375734329, 0.004305291920900345, 0.05816362053155899, 0.10638436675071716, 0.11971519887447357, -0.15064489841461182, 0.027983732521533966, 0.09820358455181122, 0.006170953158289194, -0.09354434162378311, -0.06714819371700287, 0.02495068497955799, -0.04053304344415665, 0.058805763721466064, -0.191281259059906, -0.04615461081266403, 0.18386398255825043, -0.088046133518219, -0.14949820935726166, -0.11574295908212662, 0.02608766034245491, -0.03772781789302826, -0.08589161932468414, -0.0374675989151001, 0.0978202074766159, 0.03525751456618309, 0.09679247438907623, -0.028677914291620255, -0.06499546766281128, -0.052882589399814606, -0.04895502328872681, 0.022524258121848106, -0.13324199616909027, -0.10099594295024872, 0.008664492517709732, 0.04236052557826042, -1.0062827016099618e-07, 0.06744839251041412, -0.058835096657276154, 0.047943711280822754, -0.12787717580795288, 0.021760109812021255, -0.07114484161138535, -0.0430595688521862, 0.06021196395158768, 0.09587203711271286, 0.1344301700592041, -0.011020738631486893, 0.07833147048950195, -0.11977126449346542, 0.030465280637145042, -0.013366643339395523, -0.10732512921094894, 0.06459887325763702, -0.02292434126138687, -0.00334727019071579, 0.019767124205827713, 0.08471105992794037, 0.0627279281616211, 0.042260535061359406, -0.06530176848173141, 0.062474325299263, -0.00949813425540924, 0.013407371938228607, -0.05815323442220688, 0.02268129587173462, 0.10631527751684189, 0.025467395782470703, -0.06919160485267639, 0.05146420747041702, -0.040850572288036346, 0.044456250965595245, -0.03274757042527199, 0.11073529720306396, 0.005738472566008568, 0.017016392201185226, 0.10504461824893951, 0.010922085493803024, -0.015314471907913685, 0.045889951288700104, 0.10564389079809189, -0.039838116616010666, -0.026711203157901764, -0.07394136488437653, 0.04280237480998039, 0.08727339655160904, -0.05794501304626465, 0.03715191408991814, -0.014289766550064087, 0.010052714496850967, -0.038381658494472504, 0.006031620316207409, 0.03378750756382942, -0.028701812028884888, -0.06952735036611557, -0.10732623189687729, 0.05018855631351471, 0.12332957237958908, -0.15470615029335022, 0.05375156179070473, 0.04415576905012131], "changes": {"1wk": -3.007283185662245}}, {"text": "3 US Stocks Estimated To Be Trading Below Their Intrinsic Value In January 2025 editorial-team@simplywallst.com (Simply Wall St) Tue, Jan 14, 2025, 5:03 PM 4 min read In This Article: AORT -1.20% ENFN -0.09% PNTG +0.57% As the U.S. stock market navigates a mixed landscape marked by fluctuating tech stocks and rising bond yields, investors are keeping a close eye on economic indicators such as inflation data and interest rate decisions from the Federal Reserve. Amidst these uncertainties, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on mispriced assets in an evolving market environment. Top 10 Undervalued Stocks Based On Cash Flows In The United States Name Current Price Fair Value (Est) Discount (Est) CareTrust REIT (NYSE:CTRE) $26.41 $51.10 48.3% Cadence Bank (NYSE:CADE) $33.81 $65.12 48.1% Camden National (NasdaqGS:CAC) $42.13 $83.83 49.7% Afya (NasdaqGS:AFYA) $15.20 $29.48 48.4% Ally Financial (NYSE:ALLY) $34.96 $69.53 49.7% Expand Energy (NasdaqGS:EXE) $102.21 $202.41 49.5% Constellium (NYSE:CSTM) $10.32 $20.58 49.9% Sociedad Qu\u00edmica y Minera de Chile (NYSE:SQM) $38.90 $75.19 48.3% South Atlantic Bancshares (OTCPK:SABK) $15.45 $30.73 49.7% Annaly Capital Management (NYSE:NLY) $18.12 $35.15 48.4% Click here to see the full list of 169 stocks from our Undervalued US Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Pennant Group Overview: The Pennant Group, Inc. provides healthcare services in the United States and has a market cap of approximately $886.87 million. Operations: Revenue segments include Senior Living Services at $167.95 million and Home Health and Hospice Services at $484.35 million. Estimated Discount To Fair Value: 27.4% Pennant Group is trading at US$26.23, significantly below its estimated fair value of US$36.11, suggesting it may be undervalued based on cash flows. Despite high debt levels, earnings are forecast to grow 23.79% annually, outpacing the broader U.S. market's growth expectations. Recent strategic partnerships and leadership changes aim to enhance operational efficiency and care delivery in home health services, potentially supporting future revenue growth amidst rising demand for at-home care solutions. According our earnings growth report, there's an indication that Pennant Group might be ready to expand. Dive into the specifics of Pennant Group here with our thorough financial health report. NasdaqGS:PNTG Discounted Cash Flow as at Jan 2025 Artivion Overview: Artivion, Inc. is a global company that manufactures, processes, and distributes medical devices and implantable human tissues, with a market cap of approximately $1.25 billion. Operations: The company's revenue is primarily derived from Medical Devices, contributing $284.71 million, and Preservation Services, which adds $100.19 million. Story Continues Estimated Discount To Fair Value: 10.6% Artivion is trading at US$29.34, slightly below its estimated fair value of US$32.84, indicating potential undervaluation based on cash flows. Recent FDA approval for its AMDS Hybrid Prosthesis could enhance market position and revenue growth, projected at 9.7% annually\u2014above the U.S. market average. Despite past shareholder dilution and insider selling, Artivion's profitability outlook is positive with expected earnings growth of 123.9% per year over the next three years. The growth report we've compiled suggests that Artivion's future prospects could be on the up. Click here and access our complete balance sheet health report to understand the dynamics of Artivion. NYSE:AORT Discounted Cash Flow as at Jan 2025 Enfusion Overview: Enfusion, Inc. offers software-as-a-service solutions for the investment management industry across various regions including the United States, Europe, the Middle East, Africa, and Asia Pacific with a market cap of $1.39 billion. Operations: The company's revenue primarily comes from its online financial information provider segment, generating $195.16 million. Estimated Discount To Fair Value: 28.9% Enfusion, trading at US$10.81, is significantly undervalued with a fair value estimate of US$15.20 based on cash flows. Despite recent profit margin declines, its earnings are projected to grow 74.8% annually over the next three years\u2014well above the U.S. market average of 14.9%. The merger agreement with Clearwater Analytics values Enfusion at a premium, potentially enhancing shareholder value amidst high expected revenue growth and strong return on equity forecasts. In light of our recent growth report, it seems possible that Enfusion's financial performance will exceed current levels. Take a closer look at Enfusion's balance sheet health here in our report. NYSE:ENFN Discounted Cash Flow as at Jan 2025 Next Steps Click here to access our complete index of 169 Undervalued US Stocks Based On Cash Flows . Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management . This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:PNTG NYSE:AORT and NYSE:ENFN . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2025-01-14T14:03:02+00:00", "sentiment": {"score": -0.17537368461489677, "confidence": 0.2013961672782898, "probabilities": {"positive": 0.02602248266339302, "negative": 0.2013961672782898, "neutral": 0.7725813388824463}}, "embedding": [-0.017338957637548447, -0.1313551366329193, -0.09277575463056564, 0.022481197491288185, -0.009728793054819107, 0.00498117133975029, 0.056347399950027466, 0.049419619143009186, 0.1474006175994873, 0.021181941032409668, -0.05487886816263199, 0.015235274098813534, -0.036366112530231476, -0.039282359182834625, -0.022110581398010254, -0.023131806403398514, 0.06515525281429291, 0.015273029915988445, -0.06380704790353775, 0.09093552082777023, -0.012758544646203518, -0.07995200902223587, -0.043021004647016525, -0.03374062106013298, 0.11502178013324738, -0.017034335061907768, -0.06456753611564636, 0.008314699865877628, -0.1384677141904831, -0.12226800620555878, -0.01240663230419159, 0.05434170737862587, 0.05820475518703461, -0.04039962217211723, -0.013398896902799606, 0.04549705609679222, 0.04013329744338989, 0.05880039930343628, 0.10697583854198456, 0.037939928472042084, 0.004183490760624409, 0.03320463001728058, 0.009844032116234303, 0.005367796868085861, 0.023950649425387383, -0.11764359474182129, -0.07221557199954987, -0.0011825677938759327, 0.06825298815965652, 0.022122638300061226, -0.04546691104769707, 0.06723596900701523, -0.07434592396020889, 0.0534302219748497, -0.06905540078878403, 0.053700610995292664, -0.0498901829123497, -0.042971596121788025, 0.014263195917010307, 0.00019819103181362152, 0.02266709879040718, -0.041421663016080856, 0.09020709991455078, 0.04484579712152481, 0.09477533400058746, 0.023998087272047997, -0.0791843831539154, 0.056584250181913376, -0.11674293130636215, -0.09394863992929459, 0.07590237259864807, -0.03207080811262131, -0.13207688927650452, -0.055712196975946426, -0.08785365521907806, 0.12483486533164978, 0.11203683912754059, 0.05360467731952667, 0.06318560987710953, -0.06960725039243698, 0.024346770718693733, 0.021322183310985565, -0.07203251123428345, -0.018475407734513283, -0.02531258761882782, 0.008478165604174137, -0.0038575809448957443, 0.0718882754445076, 0.07642456889152527, 0.031211432069540024, 0.03551577776670456, 0.013493018224835396, -0.09301498532295227, -0.003030301071703434, 0.05009760707616806, 0.03999803960323334, -0.02651781216263771, -0.027075519785284996, -0.062422849237918854, 0.05335642397403717, 0.17311054468154907, 0.06255175173282623, -0.08464734256267548, -0.056521572172641754, -0.014569542370736599, -0.08564677834510803, 0.05849495157599449, -0.04608339071273804, -0.0005299018230289221, 0.004226190969347954, -0.09068498015403748, 0.07328379154205322, -0.11393851041793823, -0.04294700175523758, -0.14367160201072693, 0.020276706665754318, 0.014751952141523361, -0.10010375082492828, 0.11291410028934479, -0.01947697252035141, 0.050135258585214615, 0.1143464595079422, 0.007851023226976395, 0.05383315682411194, 0.0013202819973230362, -0.062182292342185974, -0.08806577324867249, 1.3064241442263387e-32, -0.06049198657274246, 0.031406816095113754, 0.0440792590379715, -0.10904285311698914, -0.054151274263858795, 0.050437670201063156, 0.045096255838871, -0.08186903595924377, -0.13412326574325562, 0.03050014190375805, -0.14797145128250122, 0.13122770190238953, -0.04561314359307289, -0.01839146763086319, 0.007596970535814762, -0.11891192197799683, -0.12938326597213745, -0.04283129423856735, 0.05645466595888138, -0.055600605905056, -0.027450716122984886, 0.010574568063020706, -0.06869693100452423, -0.004676893353462219, -0.03682660311460495, -0.07676655054092407, -0.17997360229492188, 0.015951013192534447, -0.0118095139041543, 0.034099653363227844, 0.006307956296950579, 0.04010026529431343, 0.012306317687034607, -0.05501275509595871, -0.031927142292261124, -0.0508720725774765, -0.07087230682373047, 0.005546474829316139, 0.04837982729077339, 0.04730794578790665, -0.08889640867710114, 0.12274044752120972, -0.044496551156044006, -0.0263303704559803, 0.040599413216114044, 0.02952485904097557, 0.062900610268116, 0.0440962128341198, 0.03299438953399658, -0.07737625390291214, -0.08688706159591675, -0.0029285575728863478, -0.07068882137537003, -0.060490552335977554, -0.09212619066238403, 0.023971743881702423, -0.02173556759953499, -0.030935848131775856, -0.050410933792591095, 0.109831303358078, -0.05297735333442688, 0.036611881107091904, -0.09662928432226181, -0.06697463989257812, -0.1590031385421753, 0.1973244547843933, 0.005599783267825842, 0.11469818651676178, -0.05011031776666641, 0.1147589236497879, 0.0293031707406044, -0.05379774421453476, 0.1526716947555542, 0.028469854965806007, 0.09475532174110413, 0.03295992687344551, 0.06367892771959305, 0.05488380789756775, 0.04457557201385498, -0.03222327306866646, -0.045157965272665024, -0.002240077592432499, -0.013992702588438988, 0.0988251268863678, 0.007071968633681536, -0.013693774119019508, 0.03974199667572975, -0.030542604625225067, -0.03644903004169464, -0.014867990277707577, -0.04593812674283981, 0.057111725211143494, 0.03722379356622696, 0.04592826962471008, -0.03732781857252121, -1.4265556995869424e-32, -0.08613462746143341, 0.017294464632868767, 0.006984678562730551, 0.05453472584486008, -0.02235565334558487, -0.04235006868839264, 0.08250291645526886, -0.027728673070669174, -0.01633249595761299, -0.09583946317434311, -0.049782685935497284, 0.03425997123122215, 0.009270052425563335, 0.04813752695918083, -0.00277785025537014, 0.0372423492372036, -0.028386399149894714, -0.04623179882764816, 0.06761303544044495, -0.1166989654302597, 0.014785466715693474, 0.16537603735923767, -0.10769322514533997, 0.1482999324798584, 0.07256026566028595, 0.12270581722259521, -0.13779398798942566, 0.026355041190981865, 0.037435371428728104, 0.03180961310863495, -0.009948549792170525, -0.002620724495500326, -0.05137961730360985, 0.08426316827535629, -0.09596762806177139, 0.011019544675946236, 0.06722641736268997, -0.06698877364397049, -0.03984875977039337, 0.05118619278073311, 0.06720102578401566, 0.015127558261156082, -0.001069420948624611, 0.04664495587348938, 0.03101307526230812, 0.054911091923713684, 0.03028983063995838, -0.040055856108665466, 0.04177026078104973, 0.0587310791015625, -0.038680341094732285, 0.01515982486307621, -0.07300811260938644, 0.2326965481042862, -0.12505200505256653, 0.09442490339279175, 0.030761010944843292, 0.015364310704171658, -0.05593189224600792, -0.06868328154087067, 0.05447870492935181, 0.15947400033473969, -0.04371696710586548, 0.02287917584180832, 0.02524060755968094, -0.03916516155004501, -0.03547969460487366, 0.001165964873507619, -0.11117586493492126, -0.09096138179302216, -0.016190528869628906, -0.10641425848007202, -0.004980186931788921, -0.23842906951904297, 0.006634480319917202, 0.18958540260791779, 0.00301494263112545, -0.05075812339782715, -0.02621648833155632, 0.09946855902671814, -0.06381665915250778, 0.09045794606208801, -0.03358200192451477, 0.07177072763442993, -0.058142244815826416, 0.11840517818927765, -0.039296653121709824, -0.05634663254022598, -0.054393112659454346, -0.0015927017666399479, -0.11226171255111694, -0.07947878539562225, -0.007866754196584225, -0.03352857753634453, -0.13324837386608124, -1.0083178381137259e-07, -0.017027433961629868, -0.08113375306129456, 0.02492423914372921, -0.06994958966970444, 0.011547260917723179, -0.020538881421089172, 0.0624614879488945, 0.03190995007753372, 0.059722740203142166, 0.13611704111099243, 0.14841243624687195, -0.0003271065652370453, -0.17800939083099365, -0.0631583109498024, -0.0636684000492096, -0.03306888788938522, -0.09127381443977356, 0.1444973647594452, -0.005635540932416916, -0.06136323884129524, 0.08651488274335861, 0.12669210135936737, -0.01179540902376175, -0.11057224869728088, -0.026043366640806198, -0.00719810463488102, -0.015222306363284588, -0.00687374547123909, 0.05397818237543106, 0.09753957390785217, 0.0021797295194119215, 0.023039385676383972, 0.13126125931739807, -0.0213523730635643, 0.07184232771396637, 0.021896444261074066, 0.07664625346660614, 0.030851522460579872, -0.026017598807811737, 0.09827706217765808, -0.03073248267173767, -0.042938634753227234, -0.08135875314474106, -0.05547606945037842, 0.07610145211219788, -0.05341118946671486, -0.08710844814777374, 0.07894690334796906, 0.11874330043792725, -0.18277625739574432, 0.0654287189245224, -0.045366957783699036, -0.02108229324221611, 0.03778794780373573, 0.04137604683637619, -0.019614772871136665, -0.15662610530853271, 0.040591754019260406, -0.1493350863456726, -0.02957763895392418, 0.03956347703933716, -0.2209327220916748, 0.062192101031541824, 0.09509920328855515], "changes": {"1wk": 3.5040397489394555}}, {"text": "New Strong Buy Stocks for January 7th Zacks Equity Research Tue, Jan 7, 2025, 3:09 PM 1 min read Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue engineering company has seen the Zacks Consensus Estimate for its current year earnings increasing 68.2% over the last 60 days. Artivion, Inc. Price and Consensus Artivion, Inc. Price and Consensus Artivion, Inc. price-consensus-chart | Artivion, Inc. Quote Vertex, Inc. VERX: This tax technology solutions provider has seen the Zacks Consensus Estimate for its current year earnings increasing 8.6% over the last 60 days. Vertex, Inc. Price and Consensus Vertex, Inc. Price and Consensus Vertex, Inc. price-consensus-chart | Vertex, Inc. Quote NextNav Inc. NN: This positioning, navigation, and timing (PNT) solutions provider has seen the Zacks Consensus Estimate for its current year earnings increasing 7.5% over the last 60 days. NextNav Inc. Price and Consensus NextNav Inc. Price and Consensus NextNav Inc. price-consensus-chart | NextNav Inc. Quote Immunocore Holdings plc IMCR: This biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 48.6% over the last 60 days. Immunocore Holdings PLC Sponsored ADR Price and Consensus Immunocore Holdings PLC Sponsored ADR Price and Consensus Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote EverQuote, Inc. EVER: This online marketplace company has seen the Zacks Consensus Estimate for its current year earnings increasing 19.7% over the last 60 days. EverQuote, Inc. Price and Consensus EverQuote, Inc. Price and Consensus EverQuote, Inc. price-consensus-chart | EverQuote, Inc. Quote You can see\u00a0the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report EverQuote, Inc. (EVER) : Free Stock Analysis Report Vertex, Inc. (VERX) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report NextNav Inc. (NN) : Free Stock Analysis Report Artivion, Inc. (AORT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2025-01-07T12:09:00+00:00", "sentiment": {"score": 0.11722936853766441, "confidence": 0.1470441371202469, "probabilities": {"positive": 0.1470441371202469, "negative": 0.029814768582582474, "neutral": 0.8231410980224609}}, "embedding": [-0.19633549451828003, -0.12307602167129517, 0.010780463926494122, 0.00113963324110955, 0.038792479783296585, -0.09107191860675812, -0.058599554002285004, 0.1633821725845337, 0.029395366087555885, 0.1291036754846573, -0.04680616036057472, 0.13266639411449432, -0.008219807408750057, 0.07114199548959732, -0.049046680331230164, 0.07175283133983612, 0.02362329512834549, -0.0017263740301132202, -0.05510947108268738, 0.04404653608798981, -0.07231684029102325, -0.00581730529665947, 0.10817542672157288, 0.002381468191742897, 0.14814293384552002, -0.01854981854557991, -0.11206971108913422, 0.03675423562526703, -0.046292368322610855, -0.1096019297838211, -0.16962946951389313, -0.0006470363587141037, 0.118344746530056, -0.03401512652635574, -0.09037533402442932, -0.1250452995300293, -0.05423744022846222, 0.06688311696052551, 0.06894479691982269, -0.007895221002399921, 0.0002580806612968445, 0.00977442879229784, -0.15609127283096313, -0.05281241238117218, -0.03550436720252037, -0.07680033147335052, -0.01100773736834526, 0.04168185591697693, 0.05989035218954086, 0.13787531852722168, -0.23365738987922668, -0.07058931887149811, 0.05088415369391441, 0.004565451294183731, -0.09900522977113724, 0.0027933260425925255, -0.16948407888412476, -0.1426340639591217, 0.09312008321285248, 0.07827427983283997, 0.0605737566947937, 0.02910657785832882, 0.06277099251747131, 0.06554548442363739, 0.08367647230625153, 0.04601480811834335, 0.004203232005238533, 0.06972162425518036, -0.04848518222570419, 0.042679574340581894, 0.013580730184912682, -0.002167460508644581, -0.11076493561267853, 0.07774711400270462, -0.02678835578262806, 0.09393482655286789, 0.08153136819601059, 0.06231033056974411, 0.11768148839473724, -0.11249332129955292, -0.005971933715045452, -0.0034857862628996372, -0.009172730147838593, -0.07586032897233963, -0.005951901897788048, -0.035584911704063416, 0.035342101007699966, 0.13191688060760498, 0.07248254120349884, -6.761401891708374e-05, 0.05767926573753357, -0.0007898462936282158, -0.043662868440151215, 0.0044943103566765785, 0.08423854410648346, 0.02319147437810898, -0.0533967986702919, 0.04961767792701721, 0.00022936519235372543, -0.051748014986515045, 0.032125186175107956, 0.07319243252277374, -0.05282421410083771, -0.03178335726261139, 0.015584586188197136, -0.08976002037525177, 0.0322880782186985, -0.042347125709056854, 0.09956527501344681, 0.06586380302906036, -0.05667160823941231, 0.09224048256874084, -0.033472415059804916, -0.025988467037677765, -0.16290220618247986, 0.0733720138669014, -0.10799510031938553, 0.03817343711853027, 0.30021506547927856, 0.04967004060745239, 0.008712726645171642, 0.04885347932577133, 0.02531224489212036, -0.0014117928221821785, 0.1199711263179779, 0.05969414860010147, -0.09920796006917953, 1.2802476482750525e-32, -0.0857870951294899, 0.08721952140331268, 0.06420132517814636, -0.07116004824638367, -0.1543145775794983, 0.04445992410182953, 0.02164509892463684, -0.004482228774577379, -0.14784333109855652, -0.07673551887273788, -0.1886518895626068, 0.002792680636048317, -0.04039165750145912, 0.08635899424552917, 0.028225649148225784, -0.13235479593276978, 0.015631306916475296, -0.003780471161007881, 0.021773040294647217, -0.072488933801651, 0.060645755380392075, 0.024261754006147385, -0.07471120357513428, 0.04563227295875549, 0.08821159601211548, -0.02576979622244835, 0.015689585357904434, 0.03093067742884159, -0.15282389521598816, 0.034563787281513214, 0.0019013388082385063, -0.03807656466960907, -0.030340038239955902, -0.008780867792665958, 0.016008293256163597, -0.06051734834909439, -0.054003678262233734, -0.005748075433075428, 0.07806406170129776, -0.03371409326791763, -0.04601770266890526, 0.06806345283985138, -0.1212763786315918, -0.156584694981575, 0.04040570184588432, -0.0002453927882015705, -0.18276503682136536, 0.07048478722572327, 0.012068336829543114, -0.05667395889759064, -0.11228585988283157, 0.024350570514798164, -0.08195366710424423, -0.05552912503480911, -0.03856184333562851, -0.005070080980658531, -0.012823857367038727, -0.011230455711483955, 0.011056932620704174, 0.17943918704986572, -0.07039292901754379, 0.10739293694496155, 0.032789211720228195, -0.09180600196123123, -0.18977347016334534, 0.1123167872428894, -0.07348567247390747, -0.0044612279161810875, -0.08244481682777405, 0.1886754035949707, 0.08372525870800018, 0.04887241870164871, 0.15284383296966553, -0.0880226120352745, 0.08115504682064056, -0.060141853988170624, -0.06840240955352783, 0.003035958856344223, -0.01905132830142975, 0.05598162114620209, -0.02208728715777397, 0.009556476958096027, -0.01990765705704689, 0.07375897467136383, 0.013576552271842957, -0.02824137732386589, 0.019909674301743507, -0.009679642505943775, 0.020003652200102806, -0.024245120584964752, 0.09896921366453171, -0.05077763646841049, -0.12303686141967773, 0.11706975102424622, -0.010688601061701775, -1.1614203038966861e-32, -0.028189653530716896, 0.05430104583501816, 0.08802462369203568, 0.05216507986187935, -0.050124745815992355, -0.04762697219848633, 0.05259913206100464, 0.11705037206411362, 0.10225880891084671, -0.08899740874767303, 0.09760485589504242, 0.07988867908716202, -0.10760167241096497, -0.05686030164361, 0.0407046377658844, 0.03517723083496094, -0.027416737750172615, -0.07659103721380234, 0.019811460748314857, 0.011868402361869812, 0.00709792785346508, 0.10680726170539856, -0.07176712155342102, 0.1646968126296997, 0.07869334518909454, 0.011368111707270145, 0.033459119498729706, 0.18651548027992249, 0.14116498827934265, -0.02953459694981575, -0.08320077508687973, -0.0281381793320179, -0.12990859150886536, 0.053365558385849, -0.010960275307297707, -0.012706008739769459, 0.05289316177368164, -0.12657368183135986, 0.03209101781249046, -0.060857728123664856, 0.1441308856010437, 0.006264362949877977, 0.009153267368674278, -0.014895260334014893, 0.09616893529891968, 0.09195596724748611, 0.04789046198129654, 0.00026483554393053055, 0.09116735309362411, 0.02382740192115307, -0.00936452578753233, 0.036716606467962265, 0.018016863614320755, 0.10488255321979523, -0.08652837574481964, -0.009239540435373783, 0.028262317180633545, 0.09201385825872421, -0.15602976083755493, -0.08160537481307983, 0.038514599204063416, 0.12270382791757584, 0.021670889109373093, 0.0394984595477581, 0.005384143441915512, 0.07569121569395065, 0.030539389699697495, -0.04467009752988815, -0.045755788683891296, -0.0864093005657196, -0.03549101576209068, -0.08423981070518494, -0.025242868810892105, -0.14355091750621796, -0.011094952933490276, 0.16838814318180084, -0.003929663449525833, -0.07129902392625809, -0.053147315979003906, -0.013817466795444489, -0.01878081075847149, 0.05725269764661789, -0.006074870470911264, -0.00863083079457283, 0.009790169075131416, 0.10574015974998474, -0.031588178128004074, 0.008135069161653519, -0.0350361242890358, 0.05053436756134033, -0.040006909519433975, -0.1209062933921814, -0.15821562707424164, 0.049933794885873795, 0.03437534719705582, -9.982396420582518e-08, 0.0686027854681015, -0.11279398202896118, 0.045057229697704315, -0.03832393139600754, 0.20411066710948944, -0.020374566316604614, 0.065310038626194, 0.0841631218791008, 0.012360082939267159, 0.14694947004318237, 0.17367376387119293, 0.05301995575428009, -0.17975224554538727, -0.027862481772899628, -0.07932518422603607, 0.012325549498200417, -0.11687992513179779, -0.020285416394472122, -0.020768046379089355, -0.1963098645210266, -0.11461539566516876, 0.05793480575084686, 0.06155099719762802, 0.003479942213743925, 0.018400423228740692, -0.02180924266576767, -0.05132952332496643, -0.10881656408309937, 0.07771594077348709, -0.027038058266043663, 0.013096390292048454, -0.026919635012745857, 0.06584222614765167, -0.05435151979327202, 0.03484419733285904, 0.004457063972949982, 0.06858770549297333, 0.02667253464460373, 0.07815930247306824, 0.11854507029056549, -0.021396061405539513, -0.021571239456534386, -0.03750760853290558, -0.034948498010635376, 0.04211494326591492, -0.0057490114122629166, -0.08920180797576904, -0.058326393365859985, 0.06871063262224197, -0.20976455509662628, 0.03691179305315018, -0.0999566912651062, 0.027032826095819473, -0.06622998416423798, -0.041330721229314804, 0.12311741709709167, -0.16292530298233032, -0.08529104292392731, 0.00521676242351532, 0.022349726408720016, 0.1288721114397049, -0.20968559384346008, 0.04172962158918381, 0.14025187492370605], "changes": {"1wk": 0.4450567346451574}}, {"text": "Best Momentum Stocks to Buy for January 7th Zacks Equity Research Tue, Jan 7, 2025, 6:15 PM 2 min read Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 7: NextNav Inc. NN: This positioning, navigation, and timing (PNT) solutions provider has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.5% over the last 60 days. NextNav Inc. Price and Consensus NextNav Inc. Price and Consensus NextNav Inc. price-consensus-chart | NextNav Inc. Quote NextNav's shares gained 72.1% over the last three months compared with the S&P 500\u2019s advanced of 3.9%. The company possesses a\u00a0Momentum Score\u00a0of A. NextNav Inc. Price NextNav Inc. Price NextNav Inc. price | NextNav Inc. Quote Vertex, Inc. VERX: This tax technology solutions provider has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.6% over the last 60 days. Vertex, Inc. Price and Consensus Vertex, Inc. Price and Consensus Vertex, Inc. price-consensus-chart | Vertex, Inc. Quote Vertex's shares gained 26.0% over the last three months compared with the S&P 500\u2019s advanced of 3.9%. The company possesses a\u00a0Momentum Score\u00a0of A. Vertex, Inc. Price Vertex, Inc. Price Vertex, Inc. price | Vertex, Inc. Quote Artivion, Inc. AORT: This medical device and tissue engineering company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 68.2% over the last 60 days. Artivion, Inc. Price and Consensus Artivion, Inc. Price and Consensus Artivion, Inc. price-consensus-chart | Artivion, Inc. Quote Artivion's shares gained 8.3% over the last three months compared with the S&P 500\u2019s advanced of 3.9%. The company possesses a Momentum Score of A. Artivion, Inc. Price Artivion, Inc. Price Artivion, Inc. price | Artivion, Inc. Quote See the full list of top ranked stocks here Learn more about the Momentum score and how it is calculated here . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex, Inc. (VERX) : Free Stock Analysis Report NextNav Inc. (NN) : Free Stock Analysis Report Artivion, Inc. (AORT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2025-01-07T15:15:00+00:00", "sentiment": {"score": 0.1752385012805462, "confidence": 0.19567885994911194, "probabilities": {"positive": 0.19567885994911194, "negative": 0.02044035866856575, "neutral": 0.7838808298110962}}, "embedding": [-0.10859920084476471, -0.0765378475189209, -0.0016984299290925264, -0.0687086433172226, -0.01459245104342699, -0.041470982134342194, -0.041617535054683685, 0.1801086962223053, 0.0872899517416954, 0.10196373611688614, -0.07440569251775742, 0.07726393640041351, 0.0013579614460468292, 0.02734028548002243, -0.0038266247138381004, -0.018577437847852707, 0.05496858060359955, -0.02242436632514, -0.05108229070901871, 0.050605908036231995, -0.07860849797725677, -0.009831412695348263, 0.09222173690795898, -0.025227945297956467, 0.17132076621055603, 0.011235080659389496, -0.0828315019607544, 0.05252540111541748, -0.03674396127462387, -0.055099353194236755, -0.06659704446792603, 0.0378720797598362, 0.05093347281217575, -0.016221284866333008, -0.07582151144742966, -0.06964804977178574, -0.10113301873207092, 0.04409432411193848, 0.09434375166893005, 0.02698892168700695, 0.0009141643531620502, 0.010296814143657684, -0.13015146553516388, -0.026393886655569077, -0.017186876386404037, -0.04394744336605072, -0.06434832513332367, -0.01039074920117855, 0.02898438274860382, 0.014756659977138042, -0.2266383171081543, -0.06678001582622528, 0.002868078649044037, -0.05663996934890747, -0.07340502738952637, 0.03848213702440262, -0.08303233981132507, -0.11075136810541153, 0.0532991997897625, -0.041853971779346466, 0.07823408395051956, -0.04893732815980911, 0.027715876698493958, 0.07725389301776886, 0.16716286540031433, 0.06115991622209549, 0.025146614760160446, 0.05034332349896431, -0.04995609074831009, 0.017128072679042816, 0.10784512758255005, 0.015965783968567848, -0.11129060387611389, 0.05779304355382919, -0.06863042712211609, 0.02989848330616951, 0.11193489283323288, 0.041604287922382355, 0.021685248240828514, -0.10095764696598053, -0.03449292480945587, -0.00714246928691864, -0.10423089563846588, -0.1132814958691597, 0.006680401973426342, -0.05348729342222214, -0.002129171509295702, 0.14464476704597473, 0.04938554763793945, 0.021212084218859673, 0.022263705730438232, -0.0720982551574707, -0.08778265863656998, -0.015048686414957047, 0.11203642189502716, 0.11698998510837555, -0.06363414227962494, -0.07913752645254135, -0.02174675278365612, 0.010995803400874138, 0.08260168135166168, 0.07534608244895935, -0.13047580420970917, -0.06398425996303558, -0.03174922987818718, -0.07237333059310913, 0.0010751112131401896, -0.018123429268598557, 0.046283598989248276, 0.037029534578323364, -0.06590595841407776, 0.059966620057821274, -0.0959692895412445, -0.09369400143623352, -0.18588750064373016, 0.038791559636592865, -0.09041419625282288, 0.08521424233913422, 0.24183641374111176, -0.001426768023520708, 0.07663735002279282, 0.0866318792104721, 0.02764267846941948, 0.0150679349899292, 0.08737212419509888, -0.032621465623378754, -0.14177283644676208, 1.1127970086324792e-32, -0.08048838376998901, 0.060588009655475616, 0.02780059352517128, -0.07662517577409744, -0.12377408146858215, 0.09207965433597565, 0.04082070291042328, -0.03387375548481941, -0.14760801196098328, -0.11403422057628632, -0.21417230367660522, -0.012341676279902458, -0.03781314194202423, -0.03171481192111969, 0.028091365471482277, -0.1309243142604828, -0.04807629436254501, 0.015040908008813858, -0.01853969320654869, -0.10004567354917526, 0.061127860099077225, 0.037125710397958755, -0.025752821937203407, 0.029898162931203842, -0.011343834921717644, -0.03263350576162338, -0.020229853689670563, -0.010689802467823029, -0.2033105492591858, 0.056329160928726196, 0.023628974333405495, -0.0301122535020113, -0.049170345067977905, -0.008775437250733376, -0.029105858877301216, -0.0021300017833709717, -0.08470180630683899, -0.012506098486483097, 0.08629848062992096, -0.07720443606376648, -0.11710309237241745, 0.06146989017724991, -0.1333901286125183, -0.11486736685037613, -0.10268422216176987, -0.016239799559116364, -0.058469660580158234, 0.05047755315899849, 0.025405270978808403, -0.08988012373447418, -0.06073230877518654, -0.04282020032405853, 0.08278065919876099, -0.0017783986404538155, -0.06881947815418243, -0.010607926174998283, 0.04199453070759773, -0.027175551280379295, -0.05271780118346214, 0.104069784283638, 0.014511284418404102, 0.11106940358877182, 0.007904279977083206, -0.07462824881076813, -0.14051741361618042, 0.13961777091026306, -0.0361965075135231, 0.07655414938926697, 0.08054520189762115, 0.15733957290649414, 0.039586879312992096, 0.06675565242767334, 0.14999116957187653, -0.08579215407371521, 0.1501874029636383, -0.012516988441348076, -0.047895245254039764, 0.06697309017181396, 0.0007750773802399635, 0.04388485476374626, -0.05201907455921173, 0.008636773563921452, -0.022114301100373268, -0.02044684626162052, 0.006122017279267311, -0.023946620523929596, 0.03925743326544762, 0.015459960326552391, -0.01811140775680542, -0.0264126043766737, 0.08113829791545868, -0.03180749714374542, -0.04585831239819527, 0.17984583973884583, 0.017239686101675034, -1.1153472436265881e-32, -0.13521534204483032, 0.09588479995727539, 0.08114643394947052, 0.10300800204277039, -0.0025893677957355976, -0.05140499398112297, 0.08320409059524536, -0.06756384670734406, -0.07767651975154877, -0.06624370813369751, 0.04894927889108658, 0.05131984502077103, -0.06709140539169312, -0.049805380403995514, 0.06422367691993713, 0.0844484493136406, 0.01574532687664032, -0.07915264368057251, 0.04082281142473221, -0.13940998911857605, 0.07428456097841263, 0.17233499884605408, -0.10145595669746399, 0.10185646265745163, 0.06726209074258804, 0.00821593962609768, 0.016849085688591003, 0.04637277498841286, 0.07171083986759186, -0.041079193353652954, 0.02917298674583435, 0.046752117574214935, -0.08124884963035583, 0.04665207862854004, -0.03250425308942795, 0.014796623960137367, -0.004232974257320166, -0.09024705737829208, 0.0057701412588357925, 0.042633578181266785, 0.13847045600414276, 0.05459044128656387, 0.13725197315216064, -0.0068388087674975395, 0.07885316759347916, 0.08894192427396774, 0.1172921359539032, -0.051161862909793854, 0.07065634429454803, 0.06749878823757172, 0.016653135418891907, 0.09845507144927979, -0.05089806392788887, 0.12944725155830383, -0.0474141389131546, 0.05817655101418495, -0.050905972719192505, 0.07346761226654053, -0.11858613044023514, -0.1093754768371582, 0.08942966163158417, 0.10507592558860779, 0.07227534055709839, 0.07706397771835327, 0.0070091113448143005, 0.05496375262737274, -0.023703638464212418, -0.07540178298950195, -0.06114398315548897, -0.0403224341571331, -0.0914420634508133, -0.041144903749227524, 0.036749254912137985, -0.11149905622005463, 0.0019859885796904564, 0.11947200447320938, 0.03873450309038162, -0.009001891128718853, -0.028961041942238808, -0.033495932817459106, -0.05677006393671036, 0.1060018241405487, -0.029797522351145744, 0.05596592277288437, -0.02948523685336113, 0.09566700458526611, 0.0014936747029423714, -0.03052949160337448, -0.0672023594379425, -0.022547166794538498, -0.09922491014003754, -0.07711392641067505, -0.043074704706668854, -0.032576628029346466, 0.03219028189778328, -1.0080507450993537e-07, -0.02406657673418522, -0.11367854475975037, -0.017863184213638306, 0.02430832013487816, 0.10378938913345337, 0.03423646092414856, 0.07944628596305847, 0.11723808944225311, 0.012645939365029335, 0.09849870204925537, 0.1947842538356781, -0.0698893666267395, -0.14004722237586975, 0.04625578224658966, -0.09816135466098785, -0.04726487398147583, -0.11378517746925354, 0.016600577160716057, -0.021935196593403816, -0.2065386027097702, 0.02913321554660797, 0.0357067808508873, -0.005433764308691025, -0.015640094876289368, -3.059394657611847e-06, 0.01697501912713051, -0.11519558727741241, -0.05731343477964401, 0.09035312384366989, -0.03751005232334137, 0.02276625856757164, -0.04145693778991699, 0.05825892090797424, -0.07799752056598663, 0.00032424088567495346, 0.05452907085418701, 0.03221043944358826, 0.10784368216991425, 0.07620902359485626, 0.22304116189479828, -0.03786749020218849, -0.031695298850536346, 0.03217272087931633, 0.05614425241947174, 0.010353825986385345, -0.05629969760775566, -0.09967160224914551, -0.014275042340159416, 0.05184497684240341, -0.22694644331932068, 0.10136725008487701, -0.07911986857652664, -0.014479744248092175, 0.02170686610043049, 0.03583129495382309, 0.0870824009180069, -0.13035249710083008, -0.028596563264727592, -0.10254548490047455, 0.0020438996143639088, 0.14367735385894775, -0.1674354076385498, -0.008642971515655518, 0.1686830222606659], "changes": {"1wk": 1.6090422301757845}}, {"text": "Artivion (AORT) Tops Q3 Earnings and Revenue Estimates Zacks Equity Research Fri, Nov 8, 2024, 2:05 AM 3 min read In This Article: SIBN +1.55% Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 300%. A quarter ago, it was expected that this biological medical device maker would post earnings of $0.03 per share when it actually produced earnings of $0.07, delivering a surprise of 133.33%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Artivion , which belongs to the Zacks Medical - Instruments industry, posted revenues of $95.78 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.66%. This compares to year-ago revenues of $87.85 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Artivion shares have added about 64.7% since the beginning of the year versus the S&P 500's gain of 24.3%. What's Next for Artivion? While Artivion has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Artivion: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.06 on $102.1 million in revenues for the coming quarter and $0.20 on $392.75 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Si-Bone (SIBN), has yet to report results for the quarter ended September 2024. The results are expected to be released on November 12. This medical device maker is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of +12%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Si-Bone's revenues are expected to be $40.49 million, up 19% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Artivion, Inc. (AORT) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2024-11-07T23:05:12+00:00", "sentiment": {"score": 0.16285113617777824, "confidence": 0.1932021826505661, "probabilities": {"positive": 0.1932021826505661, "negative": 0.030351046472787857, "neutral": 0.7764467597007751}}, "embedding": [-0.055214084684848785, 0.01730351895093918, -0.0025801677256822586, 0.09797827154397964, -0.028399573639035225, -0.026620468124747276, 0.0344458743929863, 0.09119740128517151, 0.17319877445697784, 0.0918082445859909, -0.09586238116025925, 0.11604422330856323, -0.07581233233213425, -0.026327034458518028, -0.13688620924949646, 0.031758323311805725, 0.048573631793260574, -0.05510229617357254, -0.05457166209816933, 0.063750259578228, -0.040381211787462234, -0.011972152628004551, 0.07784780859947205, -0.08323909342288971, 0.09768320620059967, 0.016125649213790894, -0.12005242705345154, 0.05088510736823082, -0.0921785831451416, -0.13731420040130615, -0.048920273780822754, 0.13557250797748566, 0.20714698731899261, -0.1037956178188324, -0.11950456351041794, -0.07490670680999756, -0.030307341367006302, 0.10140691697597504, 0.036504700779914856, 0.06548041105270386, -0.006489341147243977, 0.004491692408919334, -0.15629149973392487, -0.0720386803150177, -0.04734734445810318, -0.14632606506347656, -0.024927616119384766, -0.03388354554772377, -0.052319977432489395, 0.1600852757692337, -0.1919049322605133, -0.12742194533348083, -0.0011622626334428787, 0.018361303955316544, -0.06250043213367462, -0.034988414496183395, -0.03402174264192581, -0.09554266184568405, 0.10295477509498596, 0.05068725720047951, 0.057493921369314194, 0.08359675109386444, 0.021874038502573967, 0.035226333886384964, 0.1716424524784088, 0.017398623749613762, 0.06147261708974838, 0.10513943433761597, -0.1427246332168579, -0.02836272120475769, 0.13294729590415955, 0.008297176100313663, -0.15869149565696716, 0.0069232056848704815, 0.006376046687364578, 0.09544964134693146, 0.03614877164363861, 0.0616520494222641, 0.11515611410140991, -0.08361859619617462, 0.06878753006458282, -0.040669094771146774, -0.1270969808101654, -0.018597690388560295, 0.05354982614517212, -0.015899591147899628, 0.06454363465309143, 0.12378042191267014, 0.055512066930532455, 0.030444970354437828, -0.039709366858005524, -0.05486759543418884, -0.08600132167339325, -0.06368917971849442, 0.24296510219573975, 0.04133816808462143, -0.07912943512201309, -0.1288081556558609, 0.01720738783478737, 0.06407912820577621, 0.10457412898540497, 0.16865919530391693, -0.1294935643672943, -0.1270313560962677, 0.021841978654265404, -0.13494880497455597, 0.08990837633609772, -0.05185190960764885, 0.035757508128881454, 0.09350017458200455, 0.00793677382171154, 0.04935251921415329, -0.10012981295585632, -0.1384684145450592, -0.038915425539016724, 0.08525267243385315, -0.11931385099887848, 0.17318303883075714, 0.1678890585899353, 0.10624642670154572, 0.07245990633964539, 0.06880481541156769, -0.009574078023433685, 0.044210001826286316, 0.06937403976917267, -0.013817637227475643, -0.1466781049966812, 7.397825290738275e-33, 0.118053138256073, 0.1452595293521881, -0.026725968345999718, -0.040390368551015854, -0.02799389325082302, -0.0018611885607242584, 0.009112417697906494, -0.0449061393737793, 0.07562915980815887, -0.1104595959186554, -0.15746547281742096, 0.16832396388053894, 0.039799049496650696, -0.035899437963962555, 0.07926234602928162, -0.09302578121423721, -0.015427486971020699, 0.08556211739778519, -0.018529873341321945, 0.07028800249099731, 0.02245412766933441, -0.09706039726734161, -0.09586463868618011, 0.05854850634932518, 0.03189418464899063, 0.10338950902223587, -0.09538425505161285, 0.048012517392635345, -0.16806793212890625, 0.02618001401424408, 0.0258321650326252, 0.053187958896160126, 0.04376134276390076, -0.14638659358024597, -0.09963223338127136, -0.10101035982370377, -0.05470342934131622, -0.09107482433319092, 0.1042604148387909, 0.04664907976984978, -0.07667853683233261, 0.14452210068702698, -0.07167426496744156, -0.1302781105041504, -0.014759885147213936, 0.11376522481441498, -0.059372901916503906, 0.0370214506983757, 0.04721079766750336, 0.010575518012046814, -0.023526506498456, 0.0899195447564125, -0.027811041101813316, -0.10990101844072342, -0.05091508850455284, 0.01690969616174698, -0.14014635980129242, -0.1391393393278122, 0.04724322631955147, 0.12253949046134949, 0.08224927634000778, 0.24185629189014435, 0.10850440710783005, 0.020471913740038872, -0.26267194747924805, 0.22517168521881104, -0.019525699317455292, 0.052938222885131836, 0.002653605304658413, 0.12833045423030853, -0.02936917543411255, -0.07291959971189499, 0.05604448914527893, -0.10115291178226471, 0.10918138176202774, 0.02109798789024353, -0.00956520065665245, -0.09746846556663513, 0.025429783388972282, -0.04449129104614258, -0.058528464287519455, 0.011014873161911964, 0.06283923983573914, -0.03417033702135086, 0.053659334778785706, 0.03191481903195381, 0.04138638824224472, 0.10451289266347885, -0.03107585944235325, 0.012564927339553833, 0.07606682926416397, -0.041954778134822845, -0.12666112184524536, 0.13690945506095886, -0.04282623901963234, -7.006162327987797e-33, -0.057621218264102936, 0.05735941231250763, -0.06034460291266441, -0.04815322905778885, -0.08023497462272644, -0.02667820453643799, 0.10125987231731415, 0.1476449817419052, -0.009875975549221039, 0.07736469060182571, 0.07041314989328384, 0.01503849495202303, -0.1493915319442749, 0.04966571182012558, -0.03446200489997864, -0.07230333983898163, 0.12991461157798767, -0.14360123872756958, 0.11879029870033264, 0.03766772896051407, 0.042969606816768646, 0.250553160905838, -0.04622480273246765, 0.06596565246582031, 0.0018579906318336725, 0.14206457138061523, -0.008158746175467968, 0.11122597008943558, -0.01882263831794262, -0.08554090559482574, 0.010722218081355095, -0.09642545878887177, -0.12786521017551422, -0.006213434971868992, -0.004243244417011738, 0.025398891419172287, 0.04412754997611046, -0.22028744220733643, -0.06655875593423843, 0.01556490734219551, 0.1552780121564865, -0.01934855803847313, -0.01018192246556282, 0.027681076899170876, 0.031798988580703735, -0.03840724006295204, 0.07198680937290192, 0.07558226585388184, 0.1926267147064209, 0.02383512817323208, 0.03936877101659775, 0.032373249530792236, -0.04033251479268074, 0.1327589452266693, -0.18345212936401367, -0.02336646243929863, -0.07147088646888733, -0.013767502270638943, -0.19172993302345276, 0.030385032296180725, -0.00505245104432106, 0.14822763204574585, 0.07935353368520737, 0.029868673533201218, -0.03651784360408783, 0.15358580648899078, 0.12801067531108856, -0.016542114317417145, -0.028110742568969727, -0.0727534070611, -0.015149109996855259, -0.010927997529506683, 0.10735079646110535, -0.10709162056446075, -0.025838911533355713, 0.27670541405677795, 0.051585853099823, -0.21280699968338013, -0.03850848227739334, -0.1200014054775238, -0.07876443862915039, 0.03982444852590561, 0.03508961200714111, -0.019943561404943466, -0.1792195737361908, 0.08904938399791718, -0.03458622843027115, -0.05316381901502609, -0.05350303649902344, 0.01731821894645691, -0.09997160732746124, -0.1692962348461151, -0.1630803942680359, -0.07356138527393341, 0.03380588814616203, -1.0009053141857294e-07, 0.04004364460706711, 0.013351076282560825, 0.048050444573163986, -0.06307774037122726, 0.09271539747714996, -0.1256035417318344, 0.06310581415891647, -0.014148788526654243, 0.08825987577438354, 0.07633957266807556, 0.09206739068031311, 0.05204963684082031, -0.15920904278755188, -0.024321481585502625, -0.0122525654733181, 0.01838633045554161, -0.035310111939907074, 0.02534956857562065, -0.09821011871099472, -0.19964049756526947, -0.03400048241019249, 0.05434339866042137, 0.10516953468322754, -0.2095281183719635, 0.02131015993654728, -0.07761505246162415, -0.10091342031955719, -0.07526369392871857, 0.012597428634762764, 0.04669436067342758, 0.06852681189775467, -0.028200794011354446, 0.040130291134119034, 0.03570738807320595, -0.01592957228422165, -0.13536466658115387, 0.07695711404085159, 0.005253661889582872, 0.034045375883579254, 0.05577113851904869, 0.015351755544543266, -0.004639005288481712, 9.358488023281097e-05, 0.07002414017915726, -0.022992009297013283, -0.13856050372123718, -0.14062191545963287, -0.05627809464931488, 0.04366043955087662, -0.2105402946472168, 0.09331566840410233, -0.06813155114650726, 0.06841251254081726, -0.004718303680419922, 0.08292970061302185, 0.002064256928861141, -0.1585971713066101, -0.020854678004980087, -0.21851110458374023, 0.05210970342159271, 0.1418152004480362, -0.25937047600746155, 0.08048079162836075, 0.1134139895439148], "changes": {"1wk": -6.866804011566247, "1mo": 2.346446914827339}}, {"text": "PREMIUM Artivion Receives FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis MT Newswires Mon, Dec 9, 2024, 7:21 PM 1 min read Artivion (AORT) said Monday it has received a humanitarian device exemption from the US Food and Dru PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2024-12-09T16:21:44+00:00", "sentiment": {"score": 0.15514249075204134, "confidence": 0.1636379212141037, "probabilities": {"positive": 0.1636379212141037, "negative": 0.008495430462062359, "neutral": 0.8278666734695435}}, "embedding": [-0.14868487417697906, 0.034643787890672684, 0.1136920303106308, -0.016646822914481163, 0.14108975231647491, -0.05218610540032387, -0.014566869474947453, 0.06511923670768738, -0.03907788172364235, 0.07127916812896729, 0.14941075444221497, 0.19614697992801666, 0.033881984651088715, 0.034679487347602844, 0.01731971837580204, 0.021339641883969307, 0.1382928341627121, -0.10827604681253433, -0.0033460743725299835, 0.1475927233695984, 0.06345483660697937, 0.010798761621117592, 0.060197100043296814, -0.01742648333311081, 0.03293081745505333, -0.0024367324076592922, -0.04022292420268059, 0.06022375077009201, 0.20060953497886658, 0.003788814414292574, 0.017403706908226013, -0.15077874064445496, 0.14761844277381897, -0.12300838530063629, 0.09803653508424759, -0.019712846726179123, 0.01133984886109829, -0.10051387548446655, -0.17882902920246124, 0.05414975807070732, 0.08094948530197144, -0.17157970368862152, -0.14644500613212585, -0.013407262042164803, 0.07378584146499634, 0.01191143598407507, -0.18204660713672638, -0.10598356276750565, -0.04946455359458923, 0.15433815121650696, 0.12477624416351318, 0.006076548248529434, -0.03367670252919197, -0.07191351801156998, -0.023234175518155098, -0.2668456435203552, -0.031795140355825424, -0.07966364920139313, 0.024780716747045517, -0.06541167199611664, -0.017427092418074608, -0.0028403373435139656, 0.02024729736149311, 0.11804188787937164, -0.1444382518529892, 0.1134534701704979, 0.0281774140894413, 0.04484822228550911, 0.05056232213973999, -0.26931625604629517, 0.02029295265674591, -0.022531522437930107, 0.06511596590280533, 0.08556254208087921, 0.18961617350578308, 0.1925399899482727, 0.17499029636383057, -0.032960690557956696, 0.03896167874336243, -0.20067378878593445, -0.017932601273059845, -0.08421989530324936, 0.08579398691654205, -0.10389231145381927, 0.15391837060451508, -0.03673863783478737, -0.12778441607952118, -0.009718574583530426, 0.028725191950798035, -0.030190536752343178, 0.016280492767691612, -0.21626882255077362, 0.05258198082447052, 0.008604281581938267, 0.09855487197637558, -0.10089914500713348, -0.1295757293701172, -0.17279480397701263, -0.23432326316833496, 0.04946323111653328, -0.04015768691897392, 0.01164817251265049, -0.17143937945365906, 0.1482846438884735, -0.014562996104359627, -0.19430090487003326, -0.07107534259557724, -0.03201545029878616, 0.057367391884326935, 0.10242317616939545, 0.12280131131410599, 0.09850852936506271, 0.1818927675485611, -0.10369245707988739, -0.16311226785182953, 0.0688878521323204, -0.25964048504829407, -0.04617844521999359, 0.3215844929218292, -0.13782794773578644, -0.18061257898807526, -0.10907118022441864, -0.020050831139087677, -0.05484114959836006, 0.1219068169593811, -0.04150177910923958, -0.012504254467785358, 1.2456319845056255e-32, 0.06681615114212036, 0.06674972176551819, 0.07124509662389755, -0.10990390926599503, -0.08569631725549698, -0.05559796094894409, -0.0826970711350441, -0.09279131144285202, 0.04306122660636902, -0.1397489607334137, -0.1130707636475563, 0.14683762192726135, 0.06909676641225815, 0.15824778378009796, 0.038432687520980835, -0.1453547179698944, 0.04518043249845505, 0.09413774311542511, 0.17640729248523712, 0.11419297754764557, -0.05408643186092377, -0.1625441312789917, 0.010272212326526642, 0.09622291475534439, 0.030504891648888588, 0.17642730474472046, 0.013986630365252495, 0.060386814177036285, 0.09319152683019638, 0.13642415404319763, -0.1984235793352127, 0.012032941915094852, 0.0553131029009819, -0.024586929008364677, 0.09570442885160446, 0.1615016907453537, -0.13379445672035217, -0.07242845743894577, -0.1586616337299347, -0.059874605387449265, 0.062325961887836456, -0.03065076842904091, 0.004949677269905806, -0.11086930334568024, 0.09408284723758698, -0.030899666249752045, 0.08121458441019058, -0.07611482590436935, 0.013016284443438053, -0.0453549288213253, -0.1204400509595871, 0.2960393726825714, -0.02859893999993801, -0.25838732719421387, -0.06299374997615814, -0.18837840855121613, -0.10222408175468445, 0.02385088801383972, 0.15201430022716522, 0.013472170569002628, 0.02104996144771576, 0.1764373481273651, 0.10878162831068039, 0.15393994748592377, -0.11742271482944489, 0.1553771048784256, -0.10564681142568588, -0.12670205533504486, -0.008133168332278728, 0.05885106325149536, 0.0492791049182415, -0.009702887386083603, -0.03582370653748512, -0.0418926365673542, -0.15966935455799103, 0.11433137953281403, 0.15245512127876282, 0.009694614447653294, 0.17112740874290466, -0.19035637378692627, -0.1093149334192276, 0.0761004090309143, 0.1217288076877594, 0.0500265434384346, 0.01590428315103054, -0.04379746690392494, -0.0148570341989398, -0.045040007680654526, 0.004027282353490591, 0.009119384922087193, 0.09099899977445602, -0.006981890182942152, -0.23659028112888336, 0.12660428881645203, -0.05928340181708336, -1.412386731492512e-32, -0.16930395364761353, 0.00099338055588305, 0.06859039515256882, -0.12179765850305557, -0.08515647053718567, -0.02810155227780342, 0.07722911983728409, 0.22723239660263062, 0.09267265349626541, 0.10086353868246078, 0.1297975778579712, 0.014565006829798222, -0.03989950940012932, -0.056941550225019455, 0.03551939129829407, 0.07249610126018524, -0.10875982791185379, -0.06986717134714127, -0.030233342200517654, 0.15187260508537292, 0.12286823242902756, 0.3294341266155243, 0.11943922936916351, 0.11340019106864929, 0.022043010219931602, 0.1310574859380722, -0.013645638711750507, 0.09186570346355438, -0.017873674631118774, -0.18316523730754852, 0.051031239330768585, 0.01671759970486164, -0.3001393675804138, 0.04545602574944496, -0.07024213671684265, -0.05568372830748558, 0.0999690517783165, 0.015565955080091953, -0.20506390929222107, -0.06455283612012863, 0.06497637182474136, -0.01670036092400551, -0.15582217276096344, 0.22497548162937164, 0.03183061629533768, -0.06446263194084167, 0.02842053584754467, -0.05115320160984993, 0.22383610904216766, -0.11752709746360779, -0.12476419657468796, -0.08709216862916946, 0.29791319370269775, 0.04962385818362236, -0.15105803310871124, -0.09526583552360535, 0.07802032679319382, -0.02133657969534397, -0.04676876962184906, -0.037881892174482346, 0.25360581278800964, 0.09377120435237885, -0.03945025056600571, -0.1666521430015564, -0.047033194452524185, 0.02849504165351391, 0.25985419750213623, -0.032448384910821915, -0.07764291763305664, -0.005510359071195126, 0.06981700658798218, 0.023025965318083763, -0.0715210810303688, -0.3172403872013092, 0.05669071152806282, 0.12500175833702087, 0.07092509418725967, -0.05708479508757591, -0.15356332063674927, -0.13704174757003784, -0.03789053484797478, -0.20445284247398376, -0.03693369776010513, 0.08894864469766617, -0.014756973832845688, -0.07638438791036606, 0.019996123388409615, -0.15880325436592102, -0.12476424127817154, 0.1669653356075287, -0.22869831323623657, 0.054709117859601974, -0.20167763531208038, 0.16794930398464203, -0.0006082933978177607, -9.999547501138295e-08, 0.17013274133205414, 0.09453551471233368, -0.02083909697830677, -0.00043505177018232644, -0.03697896748781204, -0.16831640899181366, -0.14238792657852173, -0.18998803198337555, -0.018920425325632095, 0.06751231104135513, 0.010038946755230427, -0.059508997946977615, -0.001050672959536314, -0.10374880582094193, 0.12425759434700012, 0.055166248232126236, 0.014171265065670013, 0.12492833286523819, -0.1508670151233673, -0.08315705507993698, -0.09461228549480438, 0.0013657748932018876, 0.1578003168106079, -0.1357015073299408, 0.024384012445807457, 0.02366439811885357, -0.0248304083943367, -0.19121241569519043, 0.09729642421007156, 0.11308418214321136, -0.0532296784222126, 0.018110333010554314, -0.113841213285923, 0.04145204275846481, -0.09457331150770187, -0.0344153456389904, 0.096345916390419, 0.037352316081523895, -0.043352361768484116, 0.05259358137845993, 0.013424103148281574, -0.07981650531291962, -0.00970399845391512, 0.14052246510982513, -0.06817855685949326, 0.043969787657260895, -0.13305503129959106, -0.10912765562534332, -0.0717383325099945, 0.19096919894218445, 0.02523009292781353, -0.20224493741989136, 0.07721102237701416, -0.10649220645427704, 0.02926153689622879, 0.03439154848456383, 0.06521623581647873, -0.11188668012619019, -0.0721859335899353, 0.161448135972023, 0.2675059139728546, -0.19199790060520172, 0.1852649599313736, -0.0002502365969121456], "changes": {"1wk": -0.13793419147359914, "1mo": 4.241377731849407}}, {"text": "Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis PR Newswire Mon, Dec 9, 2024, 4:00 PM 8 min read In This Article: AORT -1.20% ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis (\"AMDS\") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. (PRNewsfoto/Artivion, Inc.) An HDE is a marketing application for a product that has been designated a Humanitarian Use Device (HUD). AMDS received both HUD and Breakthrough Designation, due to its intended benefit for patients in the treatment or diagnosis of a rare disease or condition in which no other comparable options currently exist. The HDE allows for commercial distribution of AMDS in the United States prior to anticipated approval of a Premarket Approval (\"PMA\") Application. Under the HDE, AMDS will be available as a treatment for acute DeBakey Type I dissections in the presence of malperfusion, which represent approximately 40% of all acute DeBakey Type I\u00a0dissections in the U.S. The PMA, if approved, is expected to cover all acute DeBakey Type I\u00a0dissections with and without malperfusion, representing an estimated $150 million annual US market opportunity. Each year, approximately 6,000 patients in the U.S. present with an acute DeBakey Type I dissection, an emergent, life-threatening medical condition that requires immediate surgical repair. Left untreated, mortality from such a dissection is reported to be approximately 1% per hour and up to 50% in the first 48 hours. Today the standard of care is an ascending replacement or hemiarch repair. While this procedure can successfully remove the primary entry tear, it fails to adequately address the remainder of the diseased aorta, resulting in complications in both the acute and long-term phases. The HDE for AMDS was granted following the availability of full cohort data from the PERSEVERE US IDE trial for AMDS. The trial consisted of 93 participants in the U.S. and met its primary endpoints demonstrating significant reduction of major adverse events (MAEs), including all-cause mortality, stroke, renal failure requiring dialysis, and myocardial infarction at 30-days following AMDS implantation. More specifically, data showed, from the use of AMDS, a 72 % reduction in all-cause mortality and a 54% reduction in primary MAEs, with zero occurrence of distal anastomotic new entry (DANE), when compared to the current standard of care hemiarch procedure. Dr. Wilson Szeto , Chief of Cardiovascular Surgery at Perelman School of Medicine at the University of Pennsylvania , recently presented the data from the PERSEVERE US IDE trial as a late-breaking abstract at the STS Annual meeting (primary endpoint results reported below). Story Continues PERSEVERE (%) Historical Reference 1 (%) Primary major adverse events (\u00b31 MAE) 26.9 58.0 All-cause mortality 9.7 34.6 New disabling stroke 10.8 20.9 New onset renal failure requiring dialysis 19.4 24.1 Myocardial infarction 0.0 10.5 Distal anastomotic new entry (DANE) 0.0 45.0 Dr. Szeto said, \"The fact that the FDA has recognized the AMDS device through the HDE pathway is very encouraging and speaks to the unique aspects of the device to treat a rare and emergent condition. The compelling results from the PERSEVERE study paired with the ease of use and approachability of the AMDS device will undoubtedly expand the ability of all cardiac surgeons to offer a more comprehensive treatment for patients.\" \"This HDE from the FDA validates the groundbreaking nature of AMDS, a device with no comparable clinical alternative,\" said Pat Mackin , Chairman, President, and Chief Executive Officer of Artivion. \"We will now work diligently with facilities and physicians in the U.S. to expand access to this life saving device as we continue to work towards PMA approval, which we still expect in late 2025. We thank every PERSEVERE investigator and study participant for helping to advance this revolutionary technology.\" Mr. Mackin added, \"We are excited to start laying the groundwork for this launch over the coming weeks and months by obtaining hospital IRB approvals, a requirement of the HDE, submitting to hospital value analysis committees (\"VAC\") and training surgeons. This will position us to begin penetrating the $150 million US market opportunity available upon PMA approval as we move through 2025.\" About the AMDS PERSEVERE Clinical Trial The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS Hybrid Prosthesis. The trial is designed to support the Company's forthcoming application to the U.S. Food and Drug Administration (FDA) for premarket approval of the AMDS. The trial consists of 93 participants in the U.S., who have experienced an acute DeBakey Type I aortic dissection. Each participant will be followed for up to 5 years. The combined 30-day safety and primary efficacy endpoints will determine the impact of the AMDS Hybrid Prosthesis on DANE prevention, reducing mortality, new disabling stroke, new onset renal failure requiring dialysis, and myocardial infarction.\u00a0 The secondary endpoint relates to remodeling of the aorta. About the AMDS Hybrid Prosthesis and Acute DeBakey Type I Aortic Dissections The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. It is used as a complement to, and in conjunction with, hemiarch replacement without adding technical complexity. The design of the AMDS allows for rapid deployment of the graft in the aortic arch during a standard replacement of the ascending aorta, with deployment adding minimal time to the procedure. The deployment of the AMDS preserves the native arch, allowing for minimally invasive re-interventions if needed, rather than an invasive arch repair. AMDS is available in select markets around the world including Europe , Canada and certain countries in Asia . The PERSEVERE clinical trial underpinning the AMDS PMA met its primary endpoints and demonstrated a 72% reduction in all-cause mortality and a 54% reduction in primary major adverse events (MAEs), with zero occurrence of distal anastomotic new entry, or DANE, when compared to the current standard of care hemiarch procedure\u00a0at 30-days following AMDS implantation. In the clinical trial (DARTS) supporting the CE Mark and Health Canada approvals, the AMDS was shown to reduce complications and reoperations in comparison to published rates with the standard of care, thereby improving the care of patients and offering potential cost savings for the health care system. Globally, approximately 48,000 patients suffer annually from acute DeBakey Type I aortic dissections, representing an estimated $150 million market opportunity in the United States and $540 million market opportunity globally, pending regulatory approvals. Aortic dissection occurs when the innermost layer of the aorta tears and blood surges through the tear separating the layers of the aorta. In acute DeBakey Type I aortic dissections, the dissection flap originates in the ascending aorta and continues down into the descending thoracic aorta. Left untreated, aortic dissections lead to death in about half of patients within the first 3 days.\u00a0The current standard of care for repairing acute DeBakey Type I aortic dissections with a primary entry tear in the ascending aorta is a hemiarch repair which involves open chest surgery during which the ascending thoracic aorta is replaced. Though this typically addresses the most critical and pressing issues resulting from acute DeBakey Type I dissections, it is often not enough. Hemiarch repair alone does not address downstream true lumen expansion or treat the false lumen beyond the ascending aorta, which could lead to costly and fatal complications such as malperfusion with subsequent end-organ ischemia resulting from a lack of blood-flow and continued pulsatile blood flow in the false lumen leading to aneurysmal growth of the aorta. About Artivion, Inc. Headquartered in suburban Atlanta, Georgia , Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com . Forward Looking Statements Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs that we will secure PMA approval for AMDS in late 2025; that our launch efforts for AMDS will position us to begin penetrating the $150M market in the US after PMA approval for AMDS as we move through 2025; and regarding our estimates of the number of patients who suffer annually from acute DeBakey Type I aortic dissections and of the annual U.S. and global market opportunities for AMDS. These forward looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including but not limited to the benefits anticipated from the Ascyrus Medical LLC transaction may not be achieved at all or at the levels we had originally anticipated; the benefits anticipated from our clinical trials, including the PERSEVERE trial, may not be achieved or achieved on our anticipated timelines and the financial and operational impact from the November 21, 2024 cybersecurity event may be more severe than currently anticipated. These risks and uncertainties also include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2023 . Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts: Artivion Lance A. Berry Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Laine Morgan Phone: 332-895-3222 investors@artivion.com References Zindovic I et al. J Thorac Cardiovasc Surg 2019; Pacini D et al. Eur J Cardiothorac Surg 2013; Girdauskas E. et al. J Thorac Cardiovasc Surg 2009; Geirsson A. et al J Thorac Cardiovasc Surg 2007; Bossone E. et al Am J Cardiol 2002 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/artivion-granted-fda-humanitarian-device-exemption-for-the-amds-hybrid-prosthesis-302325786.html SOURCE Artivion, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2024-12-09T13:00:00+00:00", "sentiment": {"score": 0.18574716243892908, "confidence": 0.1993505209684372, "probabilities": {"positive": 0.1993505209684372, "negative": 0.013603358529508114, "neutral": 0.7870460748672485}}, "embedding": [-0.13661286234855652, 0.0474257692694664, 0.13082019984722137, -0.11080366373062134, -0.10802341997623444, -0.15290243923664093, -0.08723987638950348, 0.22799010574817657, 0.08944585174322128, 0.13408224284648895, -0.059684332460165024, 0.13537836074829102, -0.01892176643013954, 0.0303131602704525, -0.11713530123233795, -0.004838149528950453, 0.04389958083629608, -0.02800004929304123, -0.1251896321773529, 0.2547072172164917, 0.13084590435028076, 0.06673601269721985, -0.04251294583082199, -0.0022894670255482197, -0.018805334344506264, -0.09901697933673859, -0.013966379687190056, 0.05135396122932434, -0.04043630510568619, 0.011054592207074165, 0.10298383235931396, -0.015454474836587906, 0.08189123123884201, -0.06200266256928444, 0.013484897091984749, 0.09090074896812439, -0.038092318922281265, -0.0036880800034850836, -0.1939249485731125, -0.019504502415657043, 0.09888118505477905, -0.048195287585258484, -0.13766077160835266, -0.03774035722017288, 0.04778362810611725, -0.06651489436626434, -0.17149530351161957, -0.011078267358243465, -0.04781604930758476, 0.15396186709403992, -0.07654649019241333, 0.002664326224476099, -0.16028285026550293, 0.13320884108543396, 0.0009556729346513748, -0.05079860985279083, -0.006569507531821728, -0.04367797449231148, -0.02886449731886387, -0.0795566514134407, -0.029572978615760803, 0.021836120635271072, 0.011108562350273132, -0.011248964816331863, -0.007763891480863094, -0.004454214591532946, 0.08227621018886566, -0.11014926433563232, 0.07258493453264236, -0.09336540102958679, 0.11435138434171677, -0.04224531352519989, -0.06723254173994064, 0.11272433400154114, 0.035728927701711655, 0.05888441950082779, 0.06569762527942657, -0.03481343761086464, 0.0015639709308743477, -0.11967531591653824, 0.06623698025941849, 0.09252403676509857, 0.05397485941648483, -0.11208055168390274, 0.119391530752182, 0.08264455944299698, -0.10536755621433258, 0.0872010737657547, 0.03578401356935501, -0.013578481040894985, -0.005497122183442116, -0.1402198076248169, 0.01957085356116295, -0.0568365752696991, 0.19672748446464539, -0.03174005448818207, -0.08414322882890701, 0.016854600980877876, -0.059971075505018234, -0.021657265722751617, 0.053994208574295044, 0.0020414795726537704, -0.14912304282188416, -0.05833454802632332, -0.04711727052927017, -0.08132487535476685, 0.029028303921222687, -0.11052475869655609, 0.0037619303911924362, -0.07323700934648514, 0.01278485544025898, 0.0007555694319307804, 0.23091939091682434, -0.08372309058904648, -0.04249342530965805, 0.12634144723415375, -0.12184692919254303, 0.02782329171895981, 0.26901108026504517, -0.009970046579837799, -0.005113582126796246, -0.04533262550830841, 0.07136254757642746, -0.104634128510952, 0.10536017268896103, 0.02659912407398224, -0.051629677414894104, 6.242722828166877e-33, 0.07369577884674072, -0.03328895568847656, -0.017403945326805115, 0.06786733865737915, -0.1327047199010849, -0.04475148394703865, -0.06734801083803177, -0.003663375973701477, 0.10662204027175903, -0.10861377418041229, -0.05761808902025223, 0.056438252329826355, 0.05163528770208359, 0.05871487036347389, -0.016127875074744225, -0.05782947689294815, 0.051934048533439636, 0.15853869915008545, -0.12069449573755264, 0.09381167590618134, -0.022314533591270447, -0.061252325773239136, -0.009315667673945427, 0.029154710471630096, 0.04462946578860283, 0.1028975322842598, -0.056211262941360474, 0.06977663934230804, -0.0034548528492450714, 0.05193281173706055, -0.11266560107469559, 0.008235529065132141, 0.03978882357478142, -0.12395787239074707, -0.054196469485759735, 0.017412550747394562, -0.09897829592227936, -0.055982958525419235, -0.04385276883840561, 0.050503022968769073, -0.0329151526093483, 0.05798707157373428, -0.05179771035909653, -0.06615661084651947, 0.11104798316955566, -0.11800254881381989, 0.038168616592884064, 0.06761671602725983, -0.06374999135732651, -0.03503698483109474, 0.012404413893818855, 0.07992297410964966, 0.06445103883743286, -0.19550132751464844, -0.06682343035936356, 0.015356034971773624, -0.029064668342471123, -0.024792959913611412, 0.11378858238458633, 0.16580919921398163, 0.0006009601056575775, 0.16933226585388184, -0.0006630867719650269, 0.23294058442115784, -0.07381013035774231, 0.11764529347419739, -0.024746734648942947, -0.04624193161725998, 0.09583637118339539, 0.02660941332578659, -0.07332582771778107, -0.0161125510931015, 0.06643323600292206, -0.08729147166013718, -0.02994432859122753, -0.009394613094627857, 0.19542163610458374, 0.14043687283992767, 0.05486221984028816, -0.20775139331817627, -0.11572424322366714, 0.10099861770868301, -0.05830264836549759, 0.007032505236566067, 0.0660003125667572, -0.002549625001847744, -0.01331748440861702, -0.06006617844104767, -0.19719266891479492, -0.07146579772233963, 0.07154812663793564, -0.05106960982084274, -0.14663566648960114, 0.04762399196624756, 0.03321212902665138, -7.856120416081145e-33, -0.14447475969791412, 0.017427191138267517, -0.02167811058461666, -0.08517376333475113, -0.02852771058678627, 0.07574605941772461, 0.1082230657339096, 0.022193362936377525, 0.0039040762931108475, -0.14374423027038574, -0.03953466936945915, 0.005836945958435535, 0.0028052530251443386, -0.06727486848831177, -0.06278975307941437, 0.11090969294309616, -0.11317406594753265, -0.17230959236621857, -0.08744952082633972, 0.14327764511108398, 0.1500178724527359, 0.2933611273765564, 0.07601501792669296, 0.03931882977485657, 0.04978029429912567, 0.07593216747045517, -0.03854190558195114, 0.021738726645708084, 0.10970260202884674, -0.09987517446279526, 0.028763165697455406, -0.019471917301416397, -0.23071613907814026, 0.019718635827302933, -0.13867142796516418, 0.027627121657133102, 0.04759761691093445, -0.10195129364728928, -0.06717779487371445, -0.08181297779083252, -0.009405842050909996, -0.0063483621925115585, -0.001132957637310028, 0.10653112828731537, -0.03167293965816498, -0.05936067923903465, 0.02171086147427559, -0.03489084169268608, 0.21829667687416077, -0.022679761052131653, -0.1386483907699585, -0.0159575417637825, 0.09413708746433258, 0.10976985096931458, -0.09132489562034607, -0.1465764343738556, 0.012237477116286755, -0.09588629007339478, -0.13734647631645203, -0.04005679488182068, 0.07534436881542206, 0.0766170397400856, 0.1233358234167099, 0.05491255968809128, 0.040806159377098083, 0.06859922409057617, 0.16663780808448792, -0.08983789384365082, -0.13552403450012207, -0.047318555414676666, 0.04452463239431381, 0.016398292034864426, -0.0340728685259819, -0.18139874935150146, 0.09175363183021545, 0.057124361395835876, 0.05174260586500168, -0.05647144466638565, -0.16738757491111755, 0.04425893351435661, -0.13326424360275269, -0.06872167438268661, -0.05839982628822327, 0.021433647722005844, 0.01595933549106121, -0.03269727900624275, 0.050920046865940094, -0.12482699006795883, -0.019479544833302498, 0.09568352997303009, -0.09817901253700256, 0.0633099377155304, -0.04538845643401146, 0.0379171296954155, -0.042713284492492676, -1.00499192967618e-07, 0.036269377917051315, 0.08967714011669159, -0.05954119563102722, -0.10631157457828522, -0.08473646640777588, -0.24662116169929504, -0.17939940094947815, 0.0731741338968277, -0.029859527945518494, 0.05115557089447975, 0.08950123935937881, 0.08559130877256393, -0.042903006076812744, -0.09544260799884796, 0.08434820175170898, -0.015114469453692436, -0.016358714550733566, 0.07638610899448395, -0.12004589289426804, -0.03747408092021942, -0.039302803575992584, -0.032504066824913025, 0.015086847357451916, -0.07014701515436172, 0.047017037868499756, 0.02696947380900383, -0.002648149151355028, -0.17532804608345032, 0.023123696446418762, 0.08287980407476425, -0.02220061793923378, 0.009946698322892189, 0.10297009348869324, 0.10238061845302582, -0.05161503702402115, -0.029305044561624527, 0.1327611207962036, 0.13730010390281677, -0.06085367500782013, 0.06624877452850342, 0.11991969496011734, -0.0365719273686409, 0.0525236614048481, 0.08735184371471405, -0.01269250363111496, -0.049119673669338226, -0.11995458602905273, 0.03248676657676697, -0.009122340939939022, 0.050457313656806946, -0.0166705884039402, -0.027864690870046616, 0.005907455459237099, -0.08663088083267212, 0.060762856155633926, 0.14951738715171814, 0.05667131394147873, -0.024532169103622437, 0.02304924838244915, 0.10398741066455841, 0.22233787178993225, -0.033640455454587936, 0.0910622626543045, 0.006752456538379192], "changes": {"1wk": -0.2413782580145474, "1mo": 0.7241347740436422}}, {"text": "Artivion Reports Third Quarter 2024 Financial Results PR Newswire Fri, Nov 8, 2024, 12:05 AM 18 min read In This Article: AORT -1.20% Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024 Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023 Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug Administration Enrollment completed in NEXUS TRIOMPHE clinical trial Received regulatory approval from the National Medical Products Administration (NMPA) to commercialize BioGlue Surgical Adhesive in China . Commercialization expected in the second half of 2025. ATLANTA , Nov. 7, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2024 . (PRNewsfoto/Artivion, Inc.) \"We continued our strong financial performance through the third quarter as our team delivered revenue growth consistent with our expectations while executing on several initiatives designed to drive long-term profitable growth with our expanding, clinically differentiated product portfolio. Revenue growth in the third quarter was driven by year-over-year growth in On-X of 15%, BioGlue of 14% and stent grafts of 12%, all compared to the third quarter of 2023. On a constant currency basis, year-over-year On-X, BioGlue, and stent grafts grew 15%, 14% and 13%, respectively. We also saw continued revenue strength across Asia Pacific and Latin America which grew 23% and 21%, respectively, and on a constant currency basis, 23% and 32%, compared to last year,\" said Pat Mackin , Chairman, President, and Chief Executive Officer. Mr. Mackin concluded, \"We also achieved important milestones in our R&D pipeline this quarter. First, BioGlue was approved in China . Second, we submitted our first module of the PMA application for AMDS with the FDA keeping us on track for an anticipated approval in Q4 2025. Third, our partner Endospan completed enrollment in its U.S. IDE trial TRIOMPHE, putting it on track for PMA approval in the second half of 2026. Fourth, excellent clinical data on 161 patients from our Evita Open Neo trial was presented as a late breaker at EACTS. That trial was larger than our upcoming Arcevo IDE trial, which gives us confidence the upcoming trial will be successful.\" Story Continues Third Quarter 2024 Financial Results Total revenues for the third quarter of 2024 were $95.8 million , an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis, both compared to the third quarter of 2023. Net loss for the third quarter of 2024 was ($2.3) million , or ($0.05) per fully diluted common share, compared to net loss of ($9.8) million , or ($0.24) per fully diluted common share for the third quarter of 2023. Non-GAAP net income for the third quarter of 2024 was $5.0 million , or $0.12 per fully diluted common share, compared to non-GAAP net income of $749,000 , or $0.02 per fully diluted common share for the third quarter of 2023. Non-GAAP net income for the third quarter of 2024 includes pretax gains related to foreign currency revaluation of $2.4 million . 2024 Financial Outlook Artivion is narrowing its revenue guidance and continues to expect constant currency revenue growth of between 10% to 12% for the full year 2024 compared to 2023 and now expects a range of $389 to $396 million for 2024 compared to the previously articulated range of $388 to $396 million . At current rates, the Company expects negligible year-over-year currency impact on the full year 2024 revenues. Additionally, Artivion continues to expect adjusted EBITDA growth of between 28% and 34% for the full year 2024 compared to 2023 resulting in an expected range of $69 to $72 million for 2024. The Company's financial performance for 2024 and future periods is subject to the risks identified below. Non-GAAP Financial Measures This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income, non-GAAP adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for the impact of changes in currency exchange. The Company's non-GAAP net income, non-GAAP adjusted EBITDA, non-GAAP general, administrative, and marketing, and free cash flows results exclude (as applicable) depreciation and amortization expense, interest income and expense, stock-based compensation expense, loss or gain on foreign currency revaluation, income tax expense or benefit, corporate rebranding expense, business development, integration, and severance income or expense, loss on extinguishment of debt, and non-cash interest expense. The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions, the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines, and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures. Webcast and Conference Call Information The company will hold a teleconference call and live webcast on November 7, 2024 , at 4:30 p.m. ET to discuss the results, followed by a question and answer session. To participate in the conference call dial 201-689-8261 a few minutes prior to 4:30 p.m. ET . The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13748263. The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations. About Artivion, Inc. Headquartered in suburban Atlanta, Georgia , Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com . Forward Looking-Statements Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include, but are not limited to, those regarding our full year revenue expectations and our confidence in our ability to meet or exceed our adjusted EBITDA target for 2024; the timeline for regulatory approval for AMDS and other products; that our revenues for the full year 2024 will be in the range of $389 and $396 million , representing revenue growth of between 10% to 12% compared to 2023 on a constant currency basis; expect, at current exchange rates, negligible currency impact on the 2024 full year revenues; and expect non-GAAP adjusted EBITDA to increase between 28% and 34% for the full year 2024 compared to 2023, resulting in non-GAAP adjusted EBITDA in the range of $69 to $72 million in 2024. These forward-looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including, but not limited to, the unpredictability of the timing and outcome of regulatory decisions, the benefits anticipated from the Ascyrus Medical LLC transaction and Endospan agreements and our operational improvements in our tissue and stent graft business may not be achieved at all or at the levels we anticipate or had originally anticipated; the benefits anticipated from our clinical trials and regulatory approvals may not be achieved or achieved on our anticipated timelines; and the benefits anticipated from our expansion into APAC and LATAM may not be achieved or achieved on our anticipated timelines. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2023 , and our Form 10-Q for the quarter ended September 30, 2024 . Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise. Artivion, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) In Thousands, Except Per Share Data (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenues: Products $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 71,244 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 63,747 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 215,568 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 192,041 Preservation services 24,535 24,107 75,661 68,293 Total revenues 95,779 87,854 291,229 260,334 Cost of products and preservation services: Products 24,412 21,574 72,707 62,084 Preservation services 10,358 10,010 31,243 30,169 Total cost of products and preservation services 34,770 31,584 103,950 92,253 Gross margin 61,009 56,270 187,279 168,081 Operating expenses: General, administrative, and marketing 50,017 51,093 130,026 158,699 Research and development 6,605 6,421 21,048 21,062 Total operating expenses 56,622 57,514 151,074 179,761 Gain from sale of non-financial assets \u2014 \u2014 \u2014 (14,250) Operating income (loss) 4,387 (1,244) 36,205 2,570 Interest expense 8,405 6,603 24,535 19,055 Interest income (366) (339) (1,093) (679) Loss on extinguishment of debt \u2014 \u2014 3,669 \u2014 Other (income) expense, net (2,386) 1,911 6 5,189 (Loss) income before income taxes (1,266) (9,419) 9,088 (20,995) Income tax expense 1,022 382 5,964 5,720 Net (loss) income $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (2,288) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (9,801) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3,124 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (26,715) (Loss) income per share: Basic $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.05) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.24) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.07 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.65) Diluted $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.05) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.24) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.07 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.65) Weighted-average common shares outstanding: Basic 41,844 40,881 41,607 40,691 Diluted 41,844 40,881 42,621 40,691 Net (loss) income $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (2,288) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (9,801) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3,124 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (26,715) Other comprehensive income (loss): Foreign currency translation adjustments 8,393 (7,070) 2,529 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (1,423) Unrealized (loss) gain from foreign currency intra-entity loans, net of tax (2,060) 2,060 (47) 1,855 Comprehensive income (loss) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 4,045 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (14,811) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5,606 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (26,283) Artivion, Inc. and Subsidiaries Condensed Consolidated Balance Sheets In Thousands September 30, 2024 December 31, 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 56,173 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 58,940 Trade receivables, net 75,686 71,796 Other receivables 2,288 2,342 Inventories, net 84,123 81,976 Deferred preservation costs, net 50,421 49,804 Prepaid expenses and other 19,267 15,810 Total current assets 287,958 280,668 Goodwill 248,745 247,337 Acquired technology, net 135,052 142,593 Operating lease right-of-use assets, net 41,206 43,822 Property and equipment, net 38,262 38,358 Other intangibles, net 29,527 29,638 Deferred income taxes 1,458 1,087 Other long-term assets 20,936 8,894 Total assets $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 803,144 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 792,397 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 11,146 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 13,318 Current portion of long-term debt 99,698 1,451 Accrued expenses 15,888 12,732 Accrued compensation 15,236 18,715 Current maturities of operating leases 4,513 3,395 Taxes payable 3,521 3,840 Accrued procurement fees 1,456 1,439 Other current liabilities 1,380 2,972 Total current liabilities 152,838 57,862 Long-term debt 214,270 305,531 Contingent consideration 51,720 63,890 Non-current maturities of operating leases 41,440 43,977 Deferred income taxes 18,538 21,851 Deferred compensation liability 7,930 6,760 Non-current finance lease obligation 3,194 3,405 Other long-term liabilities 8,475 7,341 Total liabilities $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 498,405 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 510,617 Commitments and contingencies Stockholders' equity: Preferred stock \u2014 \u2014 Common stock (75,000 shares authorized, 43,392 and 42,569 shares issued in 2024 and 2023, respectively) 434 426 Additional paid-in capital 373,264 355,919 Retained deficit (44,783) (47,907) Accumulated other comprehensive loss (9,528) (12,010) Treasury stock, at cost, 1,487 shares as of September 30, 2024 \u200eand December 31, 2023 (14,648) (14,648) Total stockholders' equity 304,739 281,780 Total liabilities and stockholders' equity $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 803,144 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 792,397 Artivion, Inc. and Subsidiaries Condensed Consolidated Statement of Cash Flows In\u00a0Thousands (Unaudited) Nine Months Ended September 30, 2024 2023 Net cash flows from operating activities: Net income (loss) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3,124 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (26,715) Adjustments to reconcile net income (loss) to net cash from operating activities: Depreciation and amortization 17,910 17,260 Change in fair value of contingent consideration (12,170) 21,900 Non-cash compensation 11,499 10,466 Non-cash lease expense 5,860 5,467 Deferred income taxes (4,187) (7,250) Non-cash debt extinguishment expense 3,669 \u2014 Write-down of inventories and deferred preservation costs 2,911 3,726 Fair value adjustment of Endospan agreements (195) 5,000 Gain from sale of non-financial assets \u2014 (14,250) Other 1,818 2,325 Changes in operating assets and liabilities: Accounts payable, accrued expenses, and other liabilities (5,237) 412 Inventories and deferred preservation costs (4,791) (10,592) Prepaid expenses and other assets (4,758) (527) Receivables (3,356) 765 Net cash flows provided by operating activities 12,097 7,987 Net cash flows from investing activities: Capital expenditures (9,763) (7,083) Payments for Endospan agreements (7,000) (5,000) Proceeds from sale of non-financial assets, net \u2014 14,250 Net cash flows (used in) provided by investing activities (16,763) 2,167 Net cash flows from financing activities: Proceeds from issuance of debt 190,000 \u2014 Proceeds from revolving credit facility 30,000 \u2014 Proceeds from exercise of stock options and issuance of common stock 5,285 3,467 Proceeds from financing insurance premiums \u2014 3,558 Repayment of debt (211,765) (2,063) Payment of debt issuance costs (10,044) \u2014 Principal payments on short-term notes payable (1,027) (1,522) Other (420) (945) Net cash flows provided by financing activities 2,029 2,495 Effect of exchange rate changes on cash and cash equivalents (130) 1,481 (Decrease) increase in cash and cash equivalents (2,767) 14,130 Cash and cash equivalents beginning of period 58,940 39,351 Cash and cash equivalents end of period $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 56,173 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 53,481 Artivion, Inc. and Subsidiaries Financial Highlights In\u00a0Thousands (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Products: Aortic stent grafts $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 28,643 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25,523 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 92,936 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80,032 On-X 21,478 18,744 61,804 54,346 Surgical sealants 18,437 16,234 53,963 49,503 Other 2,686 3,246 6,865 8,160 Total products 71,244 63,747 215,568 192,041 Preservation services 24,535 24,107 75,661 68,293 Total revenues $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 95,779 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 87,854 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 291,229 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 260,334 North America 49,089 48,028 148,679 137,541 Europe, the Middle East, and Africa 30,423 26,536 98,156 84,608 Asia Pacific 10,366 8,402 27,628 24,655 Latin America 5,901 4,888 16,766 13,530 Total revenues $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 95,779 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 87,854 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 291,229 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 260,334 Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Revenues In\u00a0Thousands (Unaudited) Revenues for the Three Months Ended September 30, Percent Change From Prior Year 2024 2023 US GAAP US GAAP Exchange Rate Effect Constant Currency Constant Currency Products: Aortic stent grafts $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 28,643 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25,523 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (208) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25,315 13\u00a0% On-X 21,478 18,744 (103) 18,641 15\u00a0% Surgical sealants 18,437 16,234 (128) 16,106 14\u00a0% Other 2,686 3,246 1 3,247 -17\u00a0% Total products 71,244 63,747 (438) 63,309 13\u00a0% Preservation services 24,535 24,107 (22) 24,085 2\u00a0% Total $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 95,779 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 87,854 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (460) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 87,394 10\u00a0% North America 49,089 48,028 (50) 47,978 2\u00a0% Europe, the Middle East, and Africa 30,423 26,536 12 26,548 15\u00a0% Asia Pacific 10,366 8,402 1 8,403 23\u00a0% Latin America 5,901 4,888 (423) 4,465 32\u00a0% Total $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 95,779 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 87,854 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (460) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 87,394 10\u00a0% Revenues for the Nine Months Ended September 30, Percent Change From Prior Year 2024 2023 US GAAP US GAAP Exchange Rate Effect Constant Currency Constant Currency Products: Aortic stent grafts $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 92,936 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80,032 688 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80,720 15\u00a0% On-X 61,804 54,346 (2) 54,344 14\u00a0% Surgical sealants 53,963 49,503 (10) 49,493 9\u00a0% Other 6,865 8,160 4 8,164 -16\u00a0% Total products 215,568 192,041 680 192,721 12\u00a0% Preservation services 75,661 68,293 (26) 68,267 11\u00a0% Total $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 291,229 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 260,334 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 654 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 260,988 12\u00a0% North America 148,679 137,541 (57) 137,484 8\u00a0% Europe, the Middle East, and Africa 98,156 84,608 994 85,602 15\u00a0% Asia Pacific 27,628 24,655 \u2014 24,655 12\u00a0% Latin America 16,766 13,530 (283) 13,247 27\u00a0% Total $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 291,229 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 260,334 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 654 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 260,988 12\u00a0% Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP General, Administrative, and Marketing Expense, Adjusted EBITDA, and Free Cash Flows In\u00a0Thousands (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Reconciliation of G&A expense, GAAP to adjusted G&A, non-GAAP: General, administrative, and marketing expense, GAAP $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50,017 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 51,093 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 130,026 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 158,699 Business development, integration, and severance expense (income) 3,431 6,363 (11,923) 22,461 Corporate rebranding expense \u2014 65 \u2014 283 Adjusted G&A, non-GAAP $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 46,586 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 44,665 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 141,949 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 135,955 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Reconciliation of net loss, GAAP to adjusted EBITDA, non-GAAP: Net (loss) income, GAAP $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (2,288) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (9,801) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3,124 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (26,715) Adjustments: Interest expense 8,405 6,603 24,535 19,055 Depreciation and amortization expense 6,110 5,759 17,910 17,260 Business development, integration, and severance expense (income) 3,431 6,122 (11,923) 26,844 Stock-based compensation expense 3,769 3,187 11,499 10,466 Income tax expense 1,022 382 5,964 5,720 Loss on extinguishment of debt \u2014 \u2014 3,669 \u2014 Interest income (366) (339) (1,093) (679) (Gain) loss on foreign currency revaluation (2,382) 1,882 (29) 112 Abandonment of CardioGenesis Cardiac laser therapy business \u2014 \u2014 \u2014 390 Corporate rebranding expense \u2014 65 \u2014 283 Gain from sale of non-financial assets \u2014 \u2014 \u2014 (14,250) Adjusted EBITDA, non-GAAP $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 17,701 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 13,860 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 53,656 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 38,486 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP: Net cash flows provided by operating activities $\u00a0\u00a0\u00a0\u00a0 11,455 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7,232 $\u00a0\u00a0\u00a0\u00a0 12,097 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7,987 Capital expenditures (3,639) (2,068) (9,763) (7,083) Free cash flows, non-GAAP $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7,816 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5,164 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 2,334 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 904 Artivion\u00a0Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Net Income\u00a0and Diluted Income Per Common Share In Thousands, Except Per Share Data (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 GAAP: (Loss) income before income taxes $\u00a0\u00a0\u00a0 (1,266) $\u00a0\u00a0\u00a0 (9,419) $\u00a0\u00a0\u00a0\u00a0\u00a0 9,088 $\u00a0 (20,995) Income tax expense 1,022 382 5,964 5,720 Net (loss) income $\u00a0\u00a0\u00a0 (2,288) $\u00a0\u00a0\u00a0 (9,801) $\u00a0\u00a0\u00a0\u00a0\u00a0 3,124 $\u00a0 (26,715) Diluted (loss) income per common share $\u00a0\u00a0\u00a0\u00a0\u00a0 (0.05) $\u00a0\u00a0\u00a0\u00a0\u00a0 (0.24) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.07 $\u00a0\u00a0\u00a0\u00a0\u00a0 (0.65) Diluted weighted-average common shares outstanding 41,844 40,881 42,621 40,691 Reconciliation of (loss) income before income taxes, GAAP to adjusted income, non-GAAP: (Loss) income before income taxes, GAAP: $\u00a0\u00a0\u00a0 (1,266) $\u00a0\u00a0\u00a0 (9,419) $\u00a0\u00a0\u00a0\u00a0\u00a0 9,088 $\u00a0 (20,995) Adjustments: Business development, integration, and severance expense (income) 3,431 6,122 (11,923) 26,844 Amortization expense 3,990 3,766 11,650 11,453 Loss on extinguishment of debt \u2014 \u2014 3,669 \u2014 Non-cash interest expense 546 465 1,610 1,391 Abandonment of CardioGenesis Cardiac laser therapy business \u2014 \u2014 \u2014 390 Corporate rebranding expense \u2014 65 \u2014 283 Gain from sale of non-financial assets \u2014 \u2014 \u2014 (14,250) Adjusted income before income taxes, non-GAAP 6,701 999 14,094 5,116 Income tax expense calculated at a tax rate of 25% 1,675 250 3,523 1,279 Adjusted net income, non-GAAP $\u00a0\u00a0\u00a0\u00a0\u00a0 5,026 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 749 $\u00a0\u00a0\u00a0 10,571 $\u00a0\u00a0\u00a0\u00a0\u00a0 3,837 Reconciliation of diluted income (loss) per common share, GAAP to adjusted diluted income per common share, non-GAAP: Diluted (loss) income per common share, GAAP: $\u00a0\u00a0\u00a0\u00a0\u00a0 (0.05) $\u00a0\u00a0\u00a0\u00a0\u00a0 (0.24) $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.07 $\u00a0\u00a0\u00a0\u00a0\u00a0 (0.65) Adjustments: Business development, integration, and severance expense (income) 0.08 0.15 (0.28) 0.65 Amortization expense 0.09 0.09 0.27 0.28 Loss on extinguishment of debt \u2014 \u2014 0.09 \u2014 Non-cash interest expense 0.02 0.01 0.04 0.03 Abandonment of CardioGenesis Cardiac laser therapy business \u2014 \u2014 \u2014 0.01 Corporate rebranding expense \u2014 \u2014 \u2014 0.01 Gain from sale of non-financial assets \u2014 \u2014 \u2014 (0.34) Tax effect of non-GAAP adjustments (0.05) (0.06) (0.03) (0.17) Effect of 25% tax rate 0.03 0.07 0.09 0.27 Adjusted diluted income per common share, non-GAAP $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.12 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.02 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.25 $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0.09 Reconciliation of diluted weighted-average common shares outstanding GAAP to diluted weighted-average common shares outstanding, non-GAAP: Diluted weighted-average common shares outstanding, GAAP: 41,844 40,881 42,621 40,691 Adjustments: Effect of dilutive stock options and awards 1,160 662 \u2014 512 Diluted weighted-average common shares outstanding, non-GAAP 43,004 41,543 42,621 41,203 Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer investors@artivion.com Phone: 770-419-3355 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/artivion-reports-third-quarter-2024-financial-results-302299294.html SOURCE Artivion, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2024-11-07T21:05:00+00:00", "sentiment": {"score": 0.9389819419011474, "confidence": 0.9537131190299988, "probabilities": {"positive": 0.9537131190299988, "negative": 0.014731177128851414, "neutral": 0.03155560791492462}}, "embedding": [-0.05073443055152893, -0.05170753598213196, -0.04971291124820709, -0.1261962652206421, -0.043201152235269547, -0.045136868953704834, -0.04997450113296509, 0.13376779854297638, 0.06453706324100494, 0.07401898503303528, -0.008030799217522144, 0.08575325459241867, -0.03784167394042015, 0.07289887964725494, 0.009531751275062561, -0.02568494714796543, 0.045014817267656326, 0.0054483916610479355, -0.07013718038797379, 0.05694446712732315, 0.13201962411403656, -0.03825262188911438, 0.03389136493206024, -0.052360475063323975, 0.05560815706849098, -0.05286744236946106, -0.10924819111824036, -0.02873845025897026, -0.09932797402143478, -0.014636973850429058, 0.005205984227359295, 0.1379135549068451, 0.06539221853017807, -0.14455533027648926, 0.0438525415956974, -0.011001204140484333, -0.08993891626596451, 0.06327112764120102, -0.15243947505950928, 0.0665910467505455, 0.08652973920106888, -0.10266901552677155, -0.13252989947795868, -0.08746878802776337, 0.050022322684526443, -0.11130283772945404, -0.08222542703151703, -0.0037068864330649376, 0.00475721713155508, 0.19233772158622742, -0.10504017025232315, -0.05103679001331329, -0.019165847450494766, 0.04167855530977249, 0.006321490742266178, -0.041974589228630066, -0.025883570313453674, -0.08015260100364685, -0.0440899059176445, -0.002930266782641411, -0.031119246035814285, 0.017396463081240654, 0.02183404564857483, 0.020120590925216675, 0.023468468338251114, -0.008284631185233593, 0.037293024361133575, -0.08240178227424622, -0.08940720558166504, -0.022797390818595886, 0.08855310827493668, -0.08424782752990723, -0.06221244856715202, 0.028475765138864517, -0.0011121544521301985, 0.16702455282211304, 0.18652644753456116, 0.10586441308259964, 0.05017651617527008, -0.13361260294914246, 0.09930935502052307, -0.013427973724901676, -0.01213012170046568, -0.0201091505587101, 0.025745294988155365, 0.057717010378837585, -0.030577169731259346, 0.05575376749038696, -0.010510630905628204, 0.018928956240415573, 0.12640300393104553, 0.08896368741989136, -0.03251684084534645, 0.062116142362356186, 0.12956826388835907, 0.012292223051190376, -0.08979304879903793, -0.1088661402463913, 0.09059946238994598, 0.016823310405015945, 0.04514732584357262, 0.11949996650218964, -0.09930526465177536, -0.11687813699245453, -0.05740611255168915, -0.14221705496311188, -0.0039167325012385845, 0.010508405975997448, 0.06924852728843689, 0.11314922571182251, -0.08575105667114258, 0.06620857119560242, 0.0006958749145269394, -0.08432205021381378, -0.07848098129034042, 0.20451821386814117, -0.18118557333946228, -0.01332144532352686, 0.30217528343200684, 0.021675195544958115, 0.03666834533214569, 0.11654720455408096, -0.04667029529809952, -0.04220934957265854, 0.057708002626895905, -0.051336612552404404, -0.05827191472053528, 9.381087033350991e-33, 0.022900808602571487, 0.027671849355101585, 0.033089280128479004, -0.0296005941927433, -0.13840407133102417, 0.09204407036304474, 0.04616348072886467, 0.011555149219930172, -0.02728625386953354, -0.18343594670295715, -0.13117118179798126, 0.07338527590036392, 0.038551025092601776, 0.06998124718666077, 0.0200878344476223, -0.12790589034557343, -0.0646190270781517, 0.1312035173177719, -0.009446500800549984, 0.05731339007616043, 0.01743810996413231, -0.056084372103214264, -0.019586026668548584, 0.09718380123376846, 0.005174429155886173, 0.08988824486732483, -0.11671222746372223, 0.008314507082104683, 0.0014098025858402252, 0.06324999034404755, 0.015944473445415497, -0.034142546355724335, 0.08351457118988037, -0.15722167491912842, -0.14526262879371643, -0.080482617020607, -0.061588436365127563, -0.117970310151577, -0.012660965323448181, 0.08967714011669159, -0.04210660606622696, 0.10081732273101807, 0.03087737038731575, -0.11810065060853958, -0.020321207121014595, 0.04492767155170441, -0.006809747312217951, 0.04337117820978165, 0.07475526630878448, -0.02975231036543846, 0.024225469678640366, 0.12478567659854889, 0.022135768085718155, -0.10676548629999161, -0.019657501950860023, -0.0244605652987957, -0.1355368196964264, -0.07884319126605988, 0.0694509893655777, 0.035801902413368225, -0.13462813198566437, 0.1751687228679657, 0.06164349615573883, 0.11444555222988129, -0.22295117378234863, 0.14813362061977386, 0.009902937337756157, 0.004506832920014858, -0.058375127613544464, 0.081009641289711, -0.010884007439017296, -0.08630242198705673, 0.05880080163478851, -0.08363890647888184, 0.0884036049246788, -0.007982959970831871, 0.06839486211538315, 0.06285809725522995, 0.015462927520275116, -0.06854003667831421, -0.11306972801685333, 0.11345230042934418, -0.025968438014388084, 0.006694971118122339, 0.0677233636379242, -0.007579497992992401, 0.05578330159187317, 0.02977859601378441, -0.02815799042582512, -0.06033070385456085, 0.0951683521270752, -0.02494093030691147, -0.12534399330615997, 0.1818714737892151, -0.020552214235067368, -1.0619485760305625e-32, -0.08197920024394989, 0.1195245087146759, -0.0006079650484025478, -0.09446482360363007, -0.024263223633170128, 0.0028333321679383516, 0.08858812600374222, 0.12234202027320862, -0.002384275197982788, -0.06446361541748047, 0.09323402494192123, 0.06520360708236694, -0.05324980616569519, -0.007413046434521675, -0.11907250434160233, -0.018682260066270828, 0.07107837498188019, -0.11218516528606415, 0.0074922554194927216, 0.1089557632803917, 0.18842287361621857, 0.2519298493862152, -0.023183291777968407, 0.13547217845916748, -0.10321375727653503, 0.11318634450435638, 0.012782392092049122, -0.0048055220395326614, 0.046592727303504944, -0.08761443197727203, 0.03320220112800598, -0.009150931611657143, -0.2895512878894806, 0.10157833248376846, -0.017366155982017517, -0.03318896144628525, 0.00872820895165205, -0.13261330127716064, -0.03126160427927971, -0.10232476890087128, 0.06579636037349701, -0.013545962981879711, -0.08580588549375534, 0.06699763983488083, 0.05263053625822067, -0.0426667183637619, 0.1055574119091034, -0.04312806576490402, 0.2562587261199951, 0.08238352090120316, -0.12739846110343933, 0.03153334930539131, 0.04247451201081276, 0.07148198783397675, -0.16647373139858246, -0.029362160712480545, 0.07149550318717957, -0.10603858530521393, -0.1531427800655365, -0.009017374366521835, -0.036696720868349075, 0.11649917811155319, 0.1788761019706726, -0.06065194681286812, 0.06025319546461105, 0.15921862423419952, 0.2511392831802368, -0.009841399267315865, 0.030242858454585075, -0.12371581047773361, 0.0063482956029474735, 0.11242968589067459, -0.03130669146776199, -0.08973647654056549, -0.024679524824023247, 0.17709699273109436, 0.05029942840337753, -0.09104909002780914, -0.12598450481891632, 0.0002175094559788704, -0.051979243755340576, 0.04551875591278076, 0.010610664263367653, -0.06243337690830231, -0.09941848367452621, -0.006250424310564995, -0.02616944909095764, -0.10396193712949753, -0.10532887279987335, 0.02888692542910576, -0.16324017941951752, -0.027005180716514587, -0.0875978171825409, 0.0364283062517643, 0.06738255172967911, -1.005064831360869e-07, 0.015887422487139702, 0.09056703746318817, 0.025028690695762634, -0.06583256274461746, -0.06564468890428543, -0.25037530064582825, -0.011959033086895943, 0.07505278289318085, 0.10622179508209229, 0.04339835047721863, 0.026633314788341522, 0.09710770845413208, -0.09163961559534073, -0.03818030655384064, -0.009022196754813194, -0.033535197377204895, -0.08686234802007675, 0.0033226003870368004, -0.07151372730731964, -0.1860864907503128, -0.08796079456806183, 0.022211333736777306, 0.10291847586631775, -0.12431890517473221, -0.05663089454174042, -0.03293909132480621, -0.03595482558012009, -0.0008337404578924179, -0.036815714091062546, 0.0527537576854229, 0.0296468585729599, -0.04030245542526245, 0.09830467402935028, 0.06320235878229141, -0.045765697956085205, -0.1999756395816803, 0.12456805258989334, 0.01812659204006195, -0.01702454686164856, 0.08544129878282547, 0.04247153177857399, -0.093211829662323, 0.08436009287834167, 0.02144724130630493, 0.019998226314783096, -0.179063081741333, -0.15597981214523315, -0.014924149960279465, 0.0988379716873169, -0.07205644994974136, 0.03601657599210739, -0.0490262396633625, -0.08053937554359436, -0.09531256556510925, 0.04799899831414223, 0.012879840098321438, -0.13119009137153625, -0.03229954466223717, -0.04965636879205704, 0.12104268372058868, 0.11158457398414612, -0.3083252012729645, 0.14299605786800385, 0.11160459369421005], "changes": {"1wk": -6.866804011566247, "1mo": 2.346446914827339}}, {"text": "Earnings To Watch: Artivion Inc (AORT) Reports Q3 2024 Result GuruFocus News Wed, Nov 6, 2024, 3:22 PM 2 min read Artivion Inc ( NYSE:AORT ) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $94.76 million, and the earnings are expected to come in at -$0.06 per share. The full year 2024's revenue is expected to be $391.95 million and the earnings are expected to be $0.06 per share. More detailed estimate data can be found on the Forecast page . Artivion Inc ( NYSE:AORT ) Estimate Trends Warning! GuruFocus has detected 5 Warning Sign with AORT. Over the past 90 days, revenue estimates for Artivion Inc ( NYSE:AORT ) for the full year 2024 have increased from $391.29 million to $391.95 million. For 2025, the estimates have risen from $429.45 million to $430.75 million. Earnings estimates have also seen an upward revision; for the full year 2024, estimates increased from -$0.05 per share to $0.06 per share, and for 2025, from -$0.04 per share to $0.20 per share. Artivion Inc ( NYSE:AORT ) Reported History In the previous quarter of 2024-06-30, Artivion Inc's ( NYSE:AORT ) actual revenue was $98.02 million, which beat analysts' revenue expectations of $97.66 million by 0.37%. Artivion Inc's ( NYSE:AORT ) actual earnings were -$0.05 per share, which beat analysts' earnings expectations of -$0.083 per share by 39.76%. After releasing the results, Artivion Inc ( NYSE:AORT ) was down by -1.89% in one day. Earnings To Watch: Artivion Inc (AORT) Reports Q3 2024 Result Artivion Inc ( NYSE:AORT ) 12 Month Price Targets Based on the one-year price targets offered by 6 analysts, the average target price for Artivion Inc ( NYSE:AORT ) is $30.77 with a high estimate of $33 and a low estimate of $29.60. The average target implies an upside of 10.31% from the current price of $27.89. Based on GuruFocus estimates, the estimated GF Value for Artivion Inc ( NYSE:AORT ) in one year is $23.47, suggesting a downside of -15.85% from the current price of $27.89. Based on the consensus recommendation from 6 brokerage firms, Artivion Inc's ( NYSE:AORT ) average brokerage recommendation is currently 1.5, indicating a \"Buy\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell. Earnings To Watch: Artivion Inc (AORT) Reports Q3 2024 Result This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AORT", "date": "2024-11-06T12:22:58+00:00", "sentiment": {"score": -0.9572961600497365, "confidence": 0.9673970937728882, "probabilities": {"positive": 0.010100933723151684, "negative": 0.9673970937728882, "neutral": 0.022502057254314423}}, "embedding": [-0.032099682837724686, -0.11862791329622269, -0.021471070125699043, 0.15787020325660706, -0.11268475651741028, 0.014854311011731625, 0.06561145931482315, 0.025484375655651093, 0.22445973753929138, 0.05650223791599274, -0.13144035637378693, 0.16974246501922607, -0.05496110022068024, 0.020634545013308525, -0.1266697347164154, 0.10617314279079437, -0.06924905627965927, -0.06655145436525345, -0.07010533660650253, 0.04102247953414917, -0.008125293999910355, -0.07870236784219742, -0.0005522724241018295, -0.17886409163475037, 0.2027624398469925, -0.0538165345788002, -0.09498439729213715, 0.03336230292916298, -0.10784891247749329, -0.11871805787086487, -0.03620597720146179, 0.03825622424483299, 0.2338617444038391, -0.0760667473077774, -0.13969242572784424, -0.04979350417852402, -0.03312346339225769, 0.09684688597917557, 0.10666298866271973, 0.05744488909840584, 0.03675777465105057, 0.005905294790863991, -0.2573113441467285, -0.06848877668380737, -0.01946135237812996, -0.09553943574428558, -0.11193285882472992, 0.03612124174833298, -0.09813858568668365, 0.26035231351852417, -0.1376379430294037, -0.12556292116641998, 0.04958462715148926, -0.08460305631160736, -0.07063177227973938, -0.08829253911972046, -0.0763651430606842, -0.09637879580259323, 0.17306244373321533, 0.03521374613046646, -0.0236411914229393, 0.046047426760196686, 0.019937114790081978, 0.08044323325157166, 0.1437450647354126, 0.04759957268834114, 0.03700118511915207, 0.14035771787166595, -0.18331754207611084, -0.06272425502538681, 0.008790622465312481, -0.0157150998711586, -0.1939934492111206, -0.03460479527711868, -0.03797971084713936, 0.17142552137374878, 0.01769903302192688, 0.03461834043264389, 0.005245594307780266, -0.11921779811382294, 0.03994721174240112, -0.039939843118190765, -0.18875831365585327, -0.014546726830303669, 0.017556082457304, 0.05754606053233147, 0.12089409679174423, 0.07610271126031876, 0.0985226258635521, 0.004168426152318716, 0.02526301145553589, -0.05019216239452362, -0.05589442700147629, 0.01563015580177307, 0.3063540458679199, 0.010542611591517925, -0.09357612580060959, -0.20156031847000122, 0.01652737520635128, 0.0783880352973938, 0.1032281368970871, 0.18748055398464203, -0.1397230178117752, -0.09738734364509583, -0.06180375814437866, -0.14872626960277557, 0.12385329604148865, -0.05522533506155014, -0.03077065758407116, 0.06676915287971497, -0.14882788062095642, 0.0844980925321579, -0.051872916519641876, -0.23876723647117615, -0.06763303279876709, 0.09118370711803436, -0.1867975890636444, 0.2169506549835205, 0.22058944404125214, -0.05945989489555359, 0.032728709280490875, 0.16213196516036987, -0.011379173956811428, 0.12242379039525986, -0.016371754929423332, -0.09575926512479782, -0.3022015690803528, 1.513612958145635e-32, 0.05628112331032753, 0.19553697109222412, -0.027444427832961082, -0.11040335148572922, -0.09677834808826447, -0.010900331661105156, 0.07009623944759369, -0.028162937611341476, -0.08196116238832474, -0.05819225311279297, -0.060152191668748856, 0.15062245726585388, 0.02446678653359413, -0.05095131695270538, 0.08299529552459717, -0.04969086870551109, 0.09625798463821411, 0.022150615230202675, -0.00619779247790575, -0.02493973635137081, 0.06068255379796028, 0.008082102984189987, -0.05674109607934952, 0.1242808997631073, 0.021290525794029236, 0.09986536204814911, -0.025052614510059357, 0.021817432716488838, -0.14331626892089844, 0.04255760833621025, 0.038526326417922974, -0.012543201446533203, 0.010742316953837872, -0.077817901968956, -0.018765117973089218, -0.10230323672294617, -0.0842745453119278, -0.009937968105077744, 0.03417321294546127, 0.03534553200006485, -0.08665576577186584, 0.12712134420871735, -0.037174440920352936, -0.19845402240753174, 0.028301630169153214, 0.09372249990701675, 0.03054317831993103, 0.03367934376001358, 0.14542219042778015, -0.0007261831779032946, -0.13747185468673706, 0.12575441598892212, -0.03180597350001335, -0.06369365751743317, 0.005057781934738159, -0.0353064090013504, -0.0768209844827652, -0.10907825082540512, 0.07274597883224487, 0.07171399891376495, 0.000981643795967102, 0.19618913531303406, 0.08702239394187927, -0.002436571754515171, -0.436393141746521, 0.2953341603279114, 0.018107611685991287, 0.11828994750976562, 0.029298055917024612, 0.19745779037475586, -0.003497181460261345, -0.05529908835887909, 0.09545144438743591, -0.044180404394865036, 0.05279949679970741, -0.01793978549540043, -0.059963636100292206, -0.05087800323963165, 0.06733258068561554, -0.013073739595711231, -0.0151133444160223, 0.10404146462678909, 0.23230360448360443, -0.09827188402414322, 0.05442048981785774, -0.026593104004859924, 0.05218486115336418, 0.1283601075410843, -0.019872155040502548, 0.06778496503829956, 0.15479600429534912, 0.011920841410756111, -0.14657318592071533, 0.20345862209796906, -0.06390871852636337, -1.4338308341241815e-32, -0.10032029449939728, 0.08784223347902298, -0.05386440455913544, -0.09131410717964172, -0.14531874656677246, -0.04871261864900589, 0.13022160530090332, 0.18711018562316895, 0.02038685977458954, 0.11257819831371307, 0.07063302397727966, -0.0055742450058460236, -0.10026337206363678, 0.08424928784370422, -0.05152668431401253, -0.04834919795393944, 0.23768185079097748, -0.20470529794692993, 0.05395744368433952, 0.045672349631786346, 0.07880836725234985, 0.21200524270534515, 0.006383910309523344, 0.11487382650375366, 0.1037747710943222, 0.14298254251480103, 0.17697545886039734, 0.05023546889424324, -0.08752422779798508, -0.09032413363456726, -0.011638281866908073, -0.14095979928970337, -0.12684805691242218, 0.08172620087862015, 0.015117611736059189, -0.009990356862545013, 0.07839477062225342, -0.16031154990196228, -0.18598735332489014, -0.04010361433029175, 0.10706748813390732, 0.051356688141822815, 0.043466150760650635, -0.1027485653758049, 0.10085812211036682, 0.02159365825355053, 0.09988649934530258, 0.06225528568029404, 0.24608556926250458, -0.021958939731121063, -0.03462054207921028, 0.09255200624465942, -0.018253829330205917, 0.08869224786758423, -0.17549926042556763, -0.05755113065242767, 0.014283325523138046, 0.10815006494522095, -0.19273695349693298, 0.04928101599216461, 0.011383754201233387, 0.1371116042137146, 0.16059111058712006, 0.032902609556913376, -0.026538264006376266, 0.13943541049957275, 0.10687148571014404, 0.011969718150794506, -0.020339032635092735, -0.18223780393600464, 0.0024318723008036613, -0.05826959386467934, -0.0387415885925293, -0.19187581539154053, -0.011032585054636002, 0.2293371558189392, 0.02875874936580658, -0.08528067171573639, -0.040512025356292725, -0.00134270079433918, -0.057309702038764954, 0.13329890370368958, -0.0151059590280056, 0.025246035307645798, -0.07430685311555862, 0.07082878053188324, -0.06158028170466423, -0.04979611560702324, -0.13814030587673187, 0.06625659763813019, -0.09295084327459335, -0.13190463185310364, -0.0716065987944603, 0.0163084976375103, 0.06412535905838013, -1.0051829235635523e-07, 0.026309462264180183, -0.010569246485829353, 0.03196203336119652, -0.09671571105718613, 0.09978768974542618, -0.19265276193618774, 0.06742458045482635, -0.013355309143662453, 0.009099123999476433, 0.0889948159456253, 0.09828292578458786, -5.552498623728752e-05, -0.2463875263929367, 0.010488510131835938, -0.043658602982759476, -0.1655624508857727, -0.11383029818534851, 0.03295006603002548, -0.005433628335595131, -0.21290597319602966, 0.1332208663225174, 0.12177667766809464, 0.12223710119724274, -0.20419570803642273, 0.06433765590190887, -0.11516998708248138, -0.06338514387607574, -0.08683472871780396, 0.007663141004741192, 0.0031328480690717697, -0.029304111376404762, -0.00808202475309372, -0.009788300842046738, -0.16286733746528625, -0.07086195051670074, -0.03335484117269516, 0.09579618275165558, 0.03308023512363434, 0.11898849904537201, 0.1720360666513443, -0.015213295817375183, -0.040622957050800323, 0.08546774089336395, 0.011389516294002533, -0.0008614547550678253, -0.052629899233579636, -0.19297483563423157, -0.12059120833873749, 0.1541680097579956, -0.31045591831207275, 0.09044462442398071, -0.06058133393526077, 0.07056489586830139, -0.015841737389564514, 0.09864123165607452, -0.07995045185089111, -0.17501428723335266, -0.0782400518655777, -0.20628803968429565, -0.004431969486176968, 0.1529882550239563, -0.43246185779571533, 0.003589024767279625, 0.10822133719921112], "changes": {"1wk": -5.808427176633632, "1mo": 0.13586619379452167}}]